| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Disease Models, Animal | 117 | 2024 | 2179 | 6.010 |
Why?
|
| Mice, SCID | 178 | 2024 | 519 | 5.690 |
Why?
|
| Mice | 450 | 2024 | 10819 | 4.700 |
Why?
|
| Mice, Inbred NOD | 140 | 2024 | 521 | 4.330 |
Why?
|
| Animals | 463 | 2024 | 20620 | 3.460 |
Why?
|
| Mice, Mutant Strains | 90 | 2014 | 302 | 3.030 |
Why?
|
| Transplantation, Heterologous | 67 | 2019 | 229 | 2.970 |
Why?
|
| Hematopoietic Stem Cells | 57 | 2024 | 285 | 2.970 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 32 | 2022 | 78 | 2.790 |
Why?
|
| T-Lymphocytes | 55 | 2024 | 1005 | 2.700 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 44 | 2024 | 350 | 2.470 |
Why?
|
| Diabetes Mellitus, Type 1 | 32 | 2024 | 620 | 2.190 |
Why?
|
| Immunologic Deficiency Syndromes | 31 | 2016 | 69 | 1.890 |
Why?
|
| Hematopoiesis | 26 | 2024 | 124 | 1.880 |
Why?
|
| Immune System | 15 | 2023 | 130 | 1.810 |
Why?
|
| Mice, Transgenic | 49 | 2024 | 1273 | 1.780 |
Why?
|
| Leukocytes, Mononuclear | 20 | 2023 | 242 | 1.720 |
Why?
|
| Insulin-Secreting Cells | 17 | 2024 | 190 | 1.710 |
Why?
|
| Mutation | 54 | 2020 | 2598 | 1.700 |
Why?
|
| Protein Tyrosine Phosphatases | 19 | 2006 | 59 | 1.700 |
Why?
|
| Islets of Langerhans Transplantation | 22 | 2024 | 176 | 1.690 |
Why?
|
| Killer Cells, Natural | 24 | 2023 | 217 | 1.670 |
Why?
|
| Mice, Inbred C57BL | 123 | 2024 | 3389 | 1.610 |
Why?
|
| Osteopetrosis | 22 | 2008 | 24 | 1.560 |
Why?
|
| Mice, Knockout | 56 | 2024 | 2105 | 1.530 |
Why?
|
| Islets of Langerhans | 22 | 2024 | 279 | 1.530 |
Why?
|
| Graft vs Host Disease | 11 | 2020 | 111 | 1.510 |
Why?
|
| Macrophage Colony-Stimulating Factor | 22 | 2008 | 32 | 1.490 |
Why?
|
| Communicable Diseases | 7 | 2016 | 90 | 1.460 |
Why?
|
| B-Lymphocytes | 42 | 2016 | 570 | 1.420 |
Why?
|
| Wound Healing | 6 | 2019 | 189 | 1.380 |
Why?
|
| Graft Survival | 37 | 2019 | 290 | 1.370 |
Why?
|
| Cell Differentiation | 64 | 2019 | 1348 | 1.330 |
Why?
|
| Skin Transplantation | 18 | 2017 | 156 | 1.270 |
Why?
|
| Thymus Gland | 39 | 2024 | 233 | 1.240 |
Why?
|
| Humans | 247 | 2024 | 62865 | 1.220 |
Why?
|
| Neoplastic Stem Cells | 15 | 2016 | 203 | 1.220 |
Why?
|
| Carrier Proteins | 8 | 2017 | 706 | 1.210 |
Why?
|
| Spleen | 64 | 2015 | 482 | 1.210 |
Why?
|
| Macrophages | 35 | 2024 | 1039 | 1.210 |
Why?
|
| Receptors, Interleukin-2 | 14 | 2015 | 71 | 1.170 |
Why?
|
| Heterografts | 7 | 2020 | 63 | 1.170 |
Why?
|
| Bone Marrow Transplantation | 33 | 2017 | 139 | 1.110 |
Why?
|
| Filariasis | 15 | 2010 | 22 | 1.010 |
Why?
|
| HIV-1 | 13 | 2023 | 719 | 1.010 |
Why?
|
| Neoplasms | 12 | 2023 | 1350 | 1.000 |
Why?
|
| Drug Resistance, Neoplasm | 10 | 2021 | 195 | 0.990 |
Why?
|
| Cell Proliferation | 19 | 2024 | 981 | 0.990 |
Why?
|
| Immunotherapy | 10 | 2023 | 251 | 0.980 |
Why?
|
| Bone Marrow | 23 | 2021 | 181 | 0.950 |
Why?
|
| Mice, Inbred BALB C | 59 | 2016 | 893 | 0.950 |
Why?
|
| Models, Animal | 11 | 2019 | 235 | 0.920 |
Why?
|
| HLA-A2 Antigen | 8 | 2015 | 64 | 0.910 |
Why?
|
| Signal Transduction | 32 | 2024 | 3027 | 0.910 |
Why?
|
| CD8-Positive T-Lymphocytes | 24 | 2024 | 671 | 0.880 |
Why?
|
| Neutrophils | 10 | 2023 | 376 | 0.870 |
Why?
|
| Graft Rejection | 16 | 2020 | 293 | 0.870 |
Why?
|
| Leukemia, Myeloid, Acute | 7 | 2021 | 190 | 0.870 |
Why?
|
| HIV Infections | 11 | 2023 | 964 | 0.860 |
Why?
|
| Brugia malayi | 15 | 2003 | 23 | 0.860 |
Why?
|
| Lung Neoplasms | 9 | 2024 | 658 | 0.850 |
Why?
|
| Autoimmune Diseases | 18 | 2008 | 231 | 0.840 |
Why?
|
| Phenotype | 27 | 2020 | 1197 | 0.840 |
Why?
|
| Flow Cytometry | 43 | 2016 | 670 | 0.830 |
Why?
|
| Membrane Proteins | 10 | 2021 | 894 | 0.820 |
Why?
|
| Antibodies, Monoclonal | 29 | 2020 | 866 | 0.800 |
Why?
|
| Keratinocytes | 7 | 2019 | 65 | 0.800 |
Why?
|
| Salmonella typhi | 5 | 2024 | 19 | 0.760 |
Why?
|
| Dendritic Cells | 19 | 2015 | 523 | 0.750 |
Why?
|
| Female | 133 | 2024 | 32566 | 0.740 |
Why?
|
| Neoplasm Transplantation | 16 | 2015 | 165 | 0.740 |
Why?
|
| Adoptive Transfer | 14 | 2020 | 149 | 0.740 |
Why?
|
| Lipoproteins | 3 | 2016 | 83 | 0.730 |
Why?
|
| ATP-Binding Cassette Transporters | 2 | 2012 | 37 | 0.720 |
Why?
|
| Precision Medicine | 2 | 2020 | 119 | 0.720 |
Why?
|
| Cord Blood Stem Cell Transplantation | 9 | 2016 | 19 | 0.710 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 20 | 2015 | 336 | 0.710 |
Why?
|
| Immunity, Innate | 15 | 2023 | 794 | 0.710 |
Why?
|
| Lymphocytes | 20 | 2015 | 200 | 0.710 |
Why?
|
| Antigens, CD34 | 17 | 2021 | 56 | 0.700 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 2 | 2019 | 26 | 0.700 |
Why?
|
| Immune System Diseases | 3 | 2019 | 17 | 0.690 |
Why?
|
| Apoptosis | 23 | 2021 | 1066 | 0.690 |
Why?
|
| Bone Marrow Cells | 31 | 2014 | 237 | 0.670 |
Why?
|
| Cell Division | 33 | 2007 | 450 | 0.670 |
Why?
|
| Mast Cells | 7 | 2019 | 38 | 0.670 |
Why?
|
| Typhoid Fever | 5 | 2024 | 21 | 0.640 |
Why?
|
| Fetal Blood | 16 | 2019 | 73 | 0.640 |
Why?
|
| Male | 108 | 2024 | 29552 | 0.640 |
Why?
|
| CD4-Positive T-Lymphocytes | 24 | 2024 | 641 | 0.640 |
Why?
|
| Guidelines as Topic | 1 | 2020 | 156 | 0.640 |
Why?
|
| Severe Combined Immunodeficiency | 14 | 2023 | 53 | 0.630 |
Why?
|
| Homeodomain Proteins | 9 | 2016 | 267 | 0.620 |
Why?
|
| Cells, Cultured | 39 | 2021 | 2155 | 0.620 |
Why?
|
| Crosses, Genetic | 21 | 2014 | 110 | 0.620 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 3 | 2008 | 8 | 0.610 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 19 | 2013 | 25 | 0.610 |
Why?
|
| Cell Line, Tumor | 24 | 2024 | 1455 | 0.600 |
Why?
|
| Keratoderma, Palmoplantar, Diffuse | 1 | 2017 | 2 | 0.570 |
Why?
|
| ErbB Receptors | 3 | 2017 | 114 | 0.570 |
Why?
|
| Cardiomyopathies | 2 | 2009 | 123 | 0.570 |
Why?
|
| Autoimmunity | 15 | 2016 | 238 | 0.570 |
Why?
|
| Inflammation | 11 | 2023 | 1142 | 0.570 |
Why?
|
| Insulin | 10 | 2024 | 687 | 0.570 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2017 | 58 | 0.560 |
Why?
|
| Protein Stability | 2 | 2015 | 91 | 0.550 |
Why?
|
| Skin | 16 | 2014 | 377 | 0.550 |
Why?
|
| Regeneration | 3 | 2019 | 96 | 0.550 |
Why?
|
| Complement System Proteins | 3 | 2017 | 115 | 0.550 |
Why?
|
| T-Lymphocytes, Regulatory | 8 | 2020 | 213 | 0.540 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2017 | 26 | 0.530 |
Why?
|
| Immune Tolerance | 13 | 2016 | 175 | 0.530 |
Why?
|
| Transplantation, Homologous | 13 | 2021 | 244 | 0.530 |
Why?
|
| Brugia pahangi | 6 | 2010 | 7 | 0.520 |
Why?
|
| T-Lymphocyte Subsets | 6 | 2010 | 248 | 0.520 |
Why?
|
| Cytokines | 10 | 2023 | 934 | 0.520 |
Why?
|
| Major Histocompatibility Complex | 6 | 2024 | 88 | 0.510 |
Why?
|
| Gene Expression Regulation | 17 | 2021 | 1614 | 0.510 |
Why?
|
| Immunohistochemistry | 25 | 2021 | 890 | 0.510 |
Why?
|
| Genes, MHC Class II | 3 | 2018 | 37 | 0.510 |
Why?
|
| Lymphocyte Activation | 20 | 2016 | 759 | 0.510 |
Why?
|
| Diabetes Mellitus, Type 2 | 5 | 2023 | 690 | 0.490 |
Why?
|
| Gene Expression Profiling | 11 | 2023 | 769 | 0.490 |
Why?
|
| Genes, MHC Class I | 2 | 2018 | 27 | 0.480 |
Why?
|
| Organ Transplantation | 2 | 2015 | 54 | 0.480 |
Why?
|
| Membrane Glycoproteins | 20 | 2012 | 669 | 0.480 |
Why?
|
| Ovarian Neoplasms | 6 | 2021 | 145 | 0.480 |
Why?
|
| Diabetes Mellitus, Experimental | 9 | 2019 | 198 | 0.470 |
Why?
|
| Antibodies, Monoclonal, Humanized | 4 | 2019 | 233 | 0.470 |
Why?
|
| Glycoproteins | 4 | 2014 | 187 | 0.470 |
Why?
|
| Antioxidants | 1 | 2017 | 252 | 0.470 |
Why?
|
| Cytotoxicity, Immunologic | 10 | 2020 | 148 | 0.470 |
Why?
|
| Glucagon-Secreting Cells | 4 | 2024 | 26 | 0.460 |
Why?
|
| Osteoclasts | 9 | 2004 | 48 | 0.460 |
Why?
|
| Gene Expression | 12 | 2021 | 838 | 0.460 |
Why?
|
| Chromosome Mapping | 15 | 2013 | 291 | 0.450 |
Why?
|
| Kidney Diseases | 2 | 2013 | 174 | 0.440 |
Why?
|
| Animals, Newborn | 18 | 2019 | 237 | 0.440 |
Why?
|
| Interleukin-6 | 7 | 2024 | 320 | 0.430 |
Why?
|
| Proto-Oncogene Proteins | 5 | 2015 | 324 | 0.430 |
Why?
|
| Phytosterols | 2 | 2012 | 8 | 0.430 |
Why?
|
| Kidney | 5 | 2014 | 444 | 0.420 |
Why?
|
| Chimera | 8 | 2007 | 42 | 0.420 |
Why?
|
| Stem Cell Factor | 8 | 2016 | 26 | 0.420 |
Why?
|
| Transcription Factors | 10 | 2018 | 1508 | 0.420 |
Why?
|
| Mice, Inbred C3H | 29 | 2010 | 176 | 0.420 |
Why?
|
| Interleukin-4 | 13 | 2014 | 141 | 0.420 |
Why?
|
| Lymphoid Tissue | 10 | 2007 | 55 | 0.420 |
Why?
|
| T-Lymphocytes, Cytotoxic | 9 | 2015 | 174 | 0.420 |
Why?
|
| Transplantation Chimera | 7 | 2017 | 40 | 0.420 |
Why?
|
| Myeloid Cells | 4 | 2021 | 94 | 0.410 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2014 | 152 | 0.410 |
Why?
|
| Immunophenotyping | 17 | 2017 | 193 | 0.410 |
Why?
|
| Interleukin-15 | 3 | 2023 | 25 | 0.400 |
Why?
|
| Interleukin-1 | 5 | 2008 | 153 | 0.400 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2012 | 36 | 0.390 |
Why?
|
| Tumor Microenvironment | 6 | 2022 | 152 | 0.390 |
Why?
|
| Rhabdomyosarcoma | 1 | 2012 | 16 | 0.390 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2013 | 125 | 0.390 |
Why?
|
| Immunoglobulins | 13 | 2008 | 77 | 0.380 |
Why?
|
| Cell Separation | 12 | 2023 | 147 | 0.380 |
Why?
|
| Immunocompetence | 6 | 2008 | 21 | 0.380 |
Why?
|
| Dystrophin | 1 | 2012 | 31 | 0.380 |
Why?
|
| Granuloma | 4 | 2010 | 41 | 0.380 |
Why?
|
| DNA Transposable Elements | 1 | 2013 | 133 | 0.380 |
Why?
|
| Aging | 14 | 2017 | 743 | 0.380 |
Why?
|
| Hyperglycemia | 5 | 2014 | 104 | 0.370 |
Why?
|
| CD40 Ligand | 17 | 2008 | 157 | 0.370 |
Why?
|
| Mice, Inbred Strains | 20 | 2010 | 189 | 0.370 |
Why?
|
| Rodent Diseases | 2 | 2010 | 6 | 0.370 |
Why?
|
| Tumor Necrosis Factor-alpha | 8 | 2010 | 613 | 0.370 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 5 | 2008 | 147 | 0.370 |
Why?
|
| Stromal Cells | 8 | 2020 | 67 | 0.360 |
Why?
|
| Lymphoma | 6 | 2024 | 101 | 0.360 |
Why?
|
| Receptors, Antigen, T-Cell | 9 | 2019 | 287 | 0.360 |
Why?
|
| Antigens, CD | 14 | 2019 | 348 | 0.360 |
Why?
|
| Dengue Virus | 4 | 2014 | 99 | 0.360 |
Why?
|
| Lymph Nodes | 15 | 2018 | 222 | 0.360 |
Why?
|
| Interleukin-2 | 4 | 2017 | 167 | 0.350 |
Why?
|
| Klebsiella oxytoca | 1 | 2010 | 2 | 0.350 |
Why?
|
| Homozygote | 18 | 2013 | 124 | 0.350 |
Why?
|
| Osteosarcoma | 3 | 2010 | 58 | 0.350 |
Why?
|
| Animals, Laboratory | 1 | 2010 | 6 | 0.350 |
Why?
|
| Enterococcus | 1 | 2010 | 10 | 0.350 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2014 | 49 | 0.350 |
Why?
|
| Nephritis | 1 | 2010 | 11 | 0.350 |
Why?
|
| beta 2-Microglobulin | 8 | 2010 | 49 | 0.350 |
Why?
|
| Immunoglobulin M | 14 | 2014 | 116 | 0.340 |
Why?
|
| Microscopy, Electron | 12 | 2012 | 250 | 0.340 |
Why?
|
| Opportunistic Infections | 1 | 2010 | 30 | 0.340 |
Why?
|
| TOR Serine-Threonine Kinases | 3 | 2024 | 121 | 0.340 |
Why?
|
| Antineoplastic Agents | 8 | 2021 | 661 | 0.340 |
Why?
|
| Gene Expression Regulation, Neoplastic | 8 | 2016 | 521 | 0.330 |
Why?
|
| Lipopolysaccharides | 13 | 2019 | 644 | 0.330 |
Why?
|
| Plasma Cells | 5 | 2024 | 52 | 0.330 |
Why?
|
| Sitosterols | 1 | 2009 | 3 | 0.330 |
Why?
|
| Lipid Metabolism, Inborn Errors | 1 | 2009 | 14 | 0.330 |
Why?
|
| Bone Neoplasms | 3 | 2010 | 125 | 0.320 |
Why?
|
| Muscular Dystrophies, Limb-Girdle | 1 | 2009 | 16 | 0.320 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2024 | 68 | 0.320 |
Why?
|
| Models, Biological | 8 | 2016 | 1181 | 0.310 |
Why?
|
| Eosinophils | 8 | 2019 | 46 | 0.310 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 11 | 2014 | 545 | 0.310 |
Why?
|
| Thrombocytopenia | 1 | 2009 | 53 | 0.310 |
Why?
|
| Psoriasis | 4 | 2005 | 55 | 0.310 |
Why?
|
| Glucagon | 3 | 2024 | 33 | 0.310 |
Why?
|
| Muscle Proteins | 1 | 2009 | 118 | 0.310 |
Why?
|
| Radiation Tolerance | 4 | 2008 | 50 | 0.300 |
Why?
|
| Enzyme Inhibitors | 4 | 2014 | 373 | 0.300 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2024 | 162 | 0.300 |
Why?
|
| Immunoglobulin G | 17 | 2017 | 464 | 0.300 |
Why?
|
| Stem Cells | 15 | 2010 | 259 | 0.300 |
Why?
|
| Cell Lineage | 16 | 2018 | 268 | 0.300 |
Why?
|
| Liver | 19 | 2023 | 846 | 0.300 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 2 | 2021 | 6 | 0.300 |
Why?
|
| Immunotherapy, Adoptive | 7 | 2016 | 96 | 0.300 |
Why?
|
| Interferon-gamma | 15 | 2013 | 567 | 0.290 |
Why?
|
| Gene Targeting | 4 | 2020 | 78 | 0.290 |
Why?
|
| HLA-A24 Antigen | 2 | 2020 | 2 | 0.290 |
Why?
|
| Leukocyte Transfusion | 3 | 2010 | 16 | 0.290 |
Why?
|
| Peritoneal Cavity | 10 | 2007 | 31 | 0.290 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 3 | 2005 | 15 | 0.290 |
Why?
|
| DNA | 8 | 2012 | 840 | 0.290 |
Why?
|
| Ichthyosis | 3 | 2008 | 8 | 0.290 |
Why?
|
| Biomarkers, Tumor | 6 | 2021 | 503 | 0.280 |
Why?
|
| Antibodies | 9 | 2012 | 182 | 0.280 |
Why?
|
| Autoantigens | 6 | 2024 | 137 | 0.280 |
Why?
|
| Anaphylaxis | 2 | 2019 | 40 | 0.280 |
Why?
|
| Real-Time Polymerase Chain Reaction | 5 | 2014 | 208 | 0.280 |
Why?
|
| Histocompatibility Antigens Class II | 5 | 1997 | 182 | 0.270 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 5 | 2016 | 73 | 0.270 |
Why?
|
| RNA, Messenger | 16 | 2017 | 1534 | 0.270 |
Why?
|
| Nerve Tissue Proteins | 4 | 2015 | 424 | 0.260 |
Why?
|
| Cell Transplantation | 7 | 2019 | 39 | 0.260 |
Why?
|
| Lymphopoiesis | 2 | 2008 | 27 | 0.260 |
Why?
|
| Ataxia Telangiectasia | 5 | 1986 | 12 | 0.260 |
Why?
|
| Pelger-Huet Anomaly | 2 | 2003 | 3 | 0.260 |
Why?
|
| CD5 Antigens | 5 | 2002 | 18 | 0.250 |
Why?
|
| Receptors, Interleukin-7 | 2 | 2005 | 16 | 0.250 |
Why?
|
| Dependovirus | 3 | 2017 | 695 | 0.250 |
Why?
|
| Burns, Chemical | 1 | 2005 | 1 | 0.250 |
Why?
|
| Corneal Diseases | 1 | 2005 | 4 | 0.250 |
Why?
|
| Eye Burns | 1 | 2005 | 2 | 0.250 |
Why?
|
| Retinal Degeneration | 1 | 2006 | 27 | 0.250 |
Why?
|
| Xenograft Model Antitumor Assays | 8 | 2021 | 189 | 0.250 |
Why?
|
| Gene Editing | 3 | 2019 | 310 | 0.250 |
Why?
|
| Autoantibodies | 10 | 2003 | 182 | 0.240 |
Why?
|
| Immunoglobulin E | 6 | 2016 | 80 | 0.240 |
Why?
|
| Breast Neoplasms | 5 | 2020 | 1194 | 0.240 |
Why?
|
| Sirolimus | 2 | 2020 | 92 | 0.240 |
Why?
|
| Lung | 13 | 2023 | 939 | 0.240 |
Why?
|
| Isoantigens | 4 | 2016 | 71 | 0.240 |
Why?
|
| Acquired Immunodeficiency Syndrome | 3 | 2016 | 138 | 0.240 |
Why?
|
| Interleukin-7 | 6 | 2019 | 30 | 0.240 |
Why?
|
| Immunization, Passive | 8 | 2001 | 108 | 0.240 |
Why?
|
| Myelopoiesis | 1 | 2005 | 14 | 0.240 |
Why?
|
| Genes, RAG-1 | 3 | 2004 | 8 | 0.240 |
Why?
|
| Proto-Oncogene Proteins c-myc | 3 | 2014 | 102 | 0.240 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 2 | 2015 | 8 | 0.240 |
Why?
|
| Blood Cell Count | 7 | 2005 | 33 | 0.230 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 11 | 2014 | 455 | 0.230 |
Why?
|
| Biomedical Research | 1 | 2008 | 264 | 0.230 |
Why?
|
| Transcriptome | 4 | 2024 | 385 | 0.230 |
Why?
|
| Genetic Linkage | 9 | 2013 | 95 | 0.230 |
Why?
|
| Mice, Nude | 12 | 2013 | 271 | 0.230 |
Why?
|
| RNA, Small Interfering | 6 | 2016 | 898 | 0.230 |
Why?
|
| Cell Movement | 6 | 2017 | 445 | 0.230 |
Why?
|
| Interleukin-3 | 5 | 2016 | 20 | 0.220 |
Why?
|
| Toll-Like Receptor 4 | 4 | 2023 | 344 | 0.220 |
Why?
|
| Transplantation Conditioning | 5 | 2017 | 102 | 0.220 |
Why?
|
| Receptors, IgG | 4 | 2019 | 38 | 0.220 |
Why?
|
| Genetic Therapy | 6 | 2017 | 771 | 0.220 |
Why?
|
| Morpholinos | 3 | 2013 | 52 | 0.220 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 3 | 2021 | 103 | 0.220 |
Why?
|
| Transplantation Tolerance | 5 | 2012 | 65 | 0.220 |
Why?
|
| Pyrimidines | 3 | 2021 | 135 | 0.220 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2017 | 187 | 0.220 |
Why?
|
| Mice, Inbred MRL lpr | 3 | 2017 | 10 | 0.220 |
Why?
|
| Species Specificity | 10 | 2020 | 336 | 0.220 |
Why?
|
| Integrin alpha6beta1 | 2 | 2015 | 34 | 0.220 |
Why?
|
| DNA-Binding Proteins | 8 | 2019 | 1184 | 0.220 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2023 | 716 | 0.220 |
Why?
|
| Longevity | 5 | 2005 | 113 | 0.210 |
Why?
|
| Skin Abnormalities | 2 | 1998 | 8 | 0.210 |
Why?
|
| Kupffer Cells | 5 | 2008 | 43 | 0.210 |
Why?
|
| Phosphorylation | 8 | 2017 | 937 | 0.210 |
Why?
|
| Base Sequence | 16 | 2013 | 1335 | 0.210 |
Why?
|
| Receptors, Immunologic | 5 | 2016 | 177 | 0.210 |
Why?
|
| Salmonella | 1 | 2024 | 44 | 0.210 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2014 | 49 | 0.210 |
Why?
|
| Adaptive Immunity | 3 | 2016 | 99 | 0.210 |
Why?
|
| Genes | 7 | 1996 | 90 | 0.210 |
Why?
|
| Colonic Neoplasms | 2 | 2016 | 220 | 0.210 |
Why?
|
| Reproducibility of Results | 3 | 2023 | 1640 | 0.210 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2024 | 181 | 0.210 |
Why?
|
| Herpesvirus 4, Human | 3 | 2013 | 195 | 0.210 |
Why?
|
| Anemia, Hemolytic | 1 | 2003 | 12 | 0.210 |
Why?
|
| Gene Rearrangement | 2 | 2021 | 41 | 0.210 |
Why?
|
| Genetic Markers | 6 | 2012 | 127 | 0.210 |
Why?
|
| Genetic Vectors | 5 | 2017 | 851 | 0.200 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 4 | 2021 | 41 | 0.200 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 3 | 2019 | 24 | 0.200 |
Why?
|
| Tumor Cells, Cultured | 9 | 2014 | 456 | 0.200 |
Why?
|
| Foreign Bodies | 1 | 2023 | 47 | 0.200 |
Why?
|
| Pancreas | 5 | 2018 | 149 | 0.200 |
Why?
|
| Receptors, Prostaglandin E, EP2 Subtype | 1 | 2022 | 2 | 0.200 |
Why?
|
| Gene Expression Regulation, Leukemic | 4 | 2021 | 51 | 0.200 |
Why?
|
| Lectins | 2 | 2019 | 42 | 0.200 |
Why?
|
| Quinolines | 2 | 2013 | 44 | 0.200 |
Why?
|
| HIV Seropositivity | 1 | 2023 | 84 | 0.200 |
Why?
|
| RNA Splicing | 2 | 2014 | 161 | 0.200 |
Why?
|
| Gene Regulatory Networks | 1 | 2023 | 158 | 0.190 |
Why?
|
| Genetic Engineering | 3 | 2020 | 115 | 0.190 |
Why?
|
| Peptide Nucleic Acids | 2 | 2012 | 16 | 0.190 |
Why?
|
| Alopecia | 2 | 2013 | 25 | 0.190 |
Why?
|
| Transplantation Immunology | 2 | 2015 | 26 | 0.190 |
Why?
|
| Antibodies, Antinuclear | 3 | 1998 | 38 | 0.190 |
Why?
|
| Vaccines | 2 | 2016 | 96 | 0.190 |
Why?
|
| Rats | 15 | 2024 | 1980 | 0.190 |
Why?
|
| Fibrosis | 3 | 2023 | 159 | 0.190 |
Why?
|
| Biomarkers | 8 | 2023 | 1388 | 0.190 |
Why?
|
| Cell Cycle | 12 | 2013 | 393 | 0.190 |
Why?
|
| Liver Neoplasms | 2 | 2015 | 295 | 0.190 |
Why?
|
| Primary Myelofibrosis | 1 | 2021 | 11 | 0.190 |
Why?
|
| Proto-Oncogene Proteins c-kit | 6 | 2017 | 32 | 0.190 |
Why?
|
| Biocompatible Materials | 1 | 2023 | 149 | 0.190 |
Why?
|
| Phosphatidylserines | 1 | 2021 | 13 | 0.190 |
Why?
|
| Thyroid Gland | 7 | 1997 | 81 | 0.190 |
Why?
|
| NF-kappa B | 4 | 2024 | 469 | 0.190 |
Why?
|
| Lymphocyte Depletion | 9 | 2014 | 99 | 0.190 |
Why?
|
| Neoplasm Metastasis | 3 | 2020 | 200 | 0.190 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 3 | 2020 | 71 | 0.190 |
Why?
|
| Serine Proteases | 1 | 2021 | 12 | 0.190 |
Why?
|
| HLA Antigens | 2 | 2011 | 63 | 0.180 |
Why?
|
| Graft vs Leukemia Effect | 1 | 2021 | 1 | 0.180 |
Why?
|
| Epstein-Barr Virus Infections | 3 | 2013 | 102 | 0.180 |
Why?
|
| Genome-Wide Association Study | 2 | 2023 | 364 | 0.180 |
Why?
|
| Zebrafish | 1 | 2024 | 345 | 0.180 |
Why?
|
| Blotting, Western | 8 | 2014 | 610 | 0.180 |
Why?
|
| Transforming Growth Factor beta | 3 | 2005 | 172 | 0.180 |
Why?
|
| Cell Line | 15 | 2018 | 2039 | 0.180 |
Why?
|
| Nasal Polyps | 2 | 2012 | 10 | 0.180 |
Why?
|
| Antigen-Presenting Cells | 5 | 2009 | 178 | 0.180 |
Why?
|
| B-Lymphocyte Subsets | 5 | 2004 | 47 | 0.180 |
Why?
|
| Dysferlin | 2 | 2012 | 11 | 0.180 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2021 | 32 | 0.180 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2013 | 73 | 0.180 |
Why?
|
| Calcineurin | 2 | 2020 | 47 | 0.180 |
Why?
|
| Immunity, Cellular | 3 | 2018 | 175 | 0.180 |
Why?
|
| Pyrroles | 3 | 2021 | 51 | 0.180 |
Why?
|
| Exosomes | 1 | 2021 | 47 | 0.180 |
Why?
|
| Cadherins | 3 | 2013 | 77 | 0.180 |
Why?
|
| Induced Pluripotent Stem Cells | 2 | 2019 | 148 | 0.180 |
Why?
|
| Dermatitis | 2 | 2014 | 28 | 0.170 |
Why?
|
| Serpins | 1 | 2020 | 18 | 0.170 |
Why?
|
| Radiation Chimera | 11 | 2006 | 58 | 0.170 |
Why?
|
| Pneumonia, Pneumocystis | 3 | 1989 | 19 | 0.170 |
Why?
|
| Glucosides | 1 | 2020 | 13 | 0.170 |
Why?
|
| Whole-Body Irradiation | 7 | 2020 | 33 | 0.170 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2020 | 29 | 0.170 |
Why?
|
| Langerhans Cells | 4 | 1993 | 11 | 0.170 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2000 | 144 | 0.170 |
Why?
|
| Antimalarials | 2 | 2013 | 124 | 0.170 |
Why?
|
| Neovascularization, Pathologic | 2 | 2018 | 140 | 0.170 |
Why?
|
| Neutropenia | 1 | 2020 | 67 | 0.170 |
Why?
|
| Models, Immunological | 3 | 2011 | 85 | 0.170 |
Why?
|
| Time Factors | 14 | 2013 | 3749 | 0.170 |
Why?
|
| Uterus | 1 | 2000 | 42 | 0.170 |
Why?
|
| Membrane Transport Proteins | 1 | 2000 | 134 | 0.170 |
Why?
|
| Endocrine Cells | 1 | 2019 | 10 | 0.170 |
Why?
|
| Pneumonia | 2 | 2002 | 288 | 0.160 |
Why?
|
| Immunoglobulin mu-Chains | 3 | 1996 | 13 | 0.160 |
Why?
|
| Interleukin-12 | 3 | 2011 | 128 | 0.160 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2021 | 101 | 0.160 |
Why?
|
| Interleukin-5 | 5 | 2001 | 36 | 0.160 |
Why?
|
| Monocytes | 6 | 2012 | 353 | 0.160 |
Why?
|
| Tacrolimus | 1 | 2020 | 65 | 0.160 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2020 | 31 | 0.160 |
Why?
|
| Microglia | 2 | 2019 | 242 | 0.160 |
Why?
|
| Benzhydryl Compounds | 1 | 2020 | 51 | 0.160 |
Why?
|
| Mice, Congenic | 2 | 2017 | 22 | 0.160 |
Why?
|
| Bacterial Proteins | 3 | 2019 | 769 | 0.160 |
Why?
|
| Gene Deletion | 8 | 2020 | 307 | 0.160 |
Why?
|
| Oxidative Stress | 2 | 2017 | 294 | 0.160 |
Why?
|
| Pemphigus | 4 | 2001 | 14 | 0.160 |
Why?
|
| Fetus | 4 | 2014 | 99 | 0.160 |
Why?
|
| Exons | 1 | 2020 | 199 | 0.160 |
Why?
|
| Cell Count | 12 | 2017 | 130 | 0.160 |
Why?
|
| Elephantiasis, Filarial | 5 | 2000 | 10 | 0.160 |
Why?
|
| Pluripotent Stem Cells | 2 | 2017 | 74 | 0.160 |
Why?
|
| Myocardium | 2 | 2012 | 275 | 0.160 |
Why?
|
| Salmonella Infections | 1 | 2019 | 42 | 0.160 |
Why?
|
| Alleles | 10 | 2008 | 449 | 0.160 |
Why?
|
| Antigens, CD20 | 2 | 2017 | 14 | 0.160 |
Why?
|
| Gene Knock-In Techniques | 1 | 2019 | 43 | 0.160 |
Why?
|
| Lymphatic Diseases | 2 | 1998 | 13 | 0.150 |
Why?
|
| Endothelium, Lymphatic | 1 | 2018 | 5 | 0.150 |
Why?
|
| CRISPR-Cas Systems | 2 | 2020 | 350 | 0.150 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 3 | 2015 | 51 | 0.150 |
Why?
|
| Bone and Bones | 4 | 1998 | 142 | 0.150 |
Why?
|
| Colony-Forming Units Assay | 7 | 2009 | 27 | 0.150 |
Why?
|
| Multiple Myeloma | 1 | 2024 | 348 | 0.150 |
Why?
|
| Nitric Oxide | 2 | 1998 | 173 | 0.150 |
Why?
|
| Translocation, Genetic | 3 | 2015 | 70 | 0.150 |
Why?
|
| Transduction, Genetic | 3 | 2020 | 236 | 0.150 |
Why?
|
| Hepatocytes | 2 | 2017 | 216 | 0.150 |
Why?
|
| Genes, Recessive | 8 | 2013 | 52 | 0.150 |
Why?
|
| Bone Density | 1 | 1999 | 134 | 0.150 |
Why?
|
| Genetic Diseases, Inborn | 2 | 2017 | 38 | 0.150 |
Why?
|
| Lipid Metabolism | 1 | 2020 | 220 | 0.150 |
Why?
|
| Leukocyte Common Antigens | 9 | 2013 | 59 | 0.150 |
Why?
|
| Dengue | 4 | 2014 | 96 | 0.150 |
Why?
|
| Toll-Like Receptors | 4 | 2009 | 431 | 0.150 |
Why?
|
| Mice, Inbred NZB | 5 | 2002 | 21 | 0.150 |
Why?
|
| Glycogen Synthase Kinase 3 | 2 | 2015 | 45 | 0.150 |
Why?
|
| Embryonic Stem Cells | 2 | 2009 | 160 | 0.150 |
Why?
|
| Nucleoside Deaminases | 2 | 1989 | 3 | 0.150 |
Why?
|
| Granulosa Cell Tumor | 3 | 1993 | 5 | 0.150 |
Why?
|
| Bone Remodeling | 1 | 1998 | 25 | 0.150 |
Why?
|
| Adenosine Deaminase | 2 | 1989 | 19 | 0.150 |
Why?
|
| Trace Elements | 1 | 1998 | 20 | 0.140 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 2018 | 133 | 0.140 |
Why?
|
| Trans-Activators | 6 | 2015 | 311 | 0.140 |
Why?
|
| Phagocytes | 1 | 2018 | 52 | 0.140 |
Why?
|
| HIV Antibodies | 1 | 2018 | 144 | 0.140 |
Why?
|
| Azepines | 2 | 2014 | 21 | 0.140 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 9 | 2001 | 17 | 0.140 |
Why?
|
| Nucleic Acid Conformation | 1 | 1998 | 242 | 0.140 |
Why?
|
| Brain | 4 | 2019 | 1554 | 0.140 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2018 | 59 | 0.140 |
Why?
|
| Glucans | 2 | 1997 | 65 | 0.140 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2017 | 24 | 0.140 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2018 | 111 | 0.140 |
Why?
|
| Transgenes | 2 | 2017 | 186 | 0.140 |
Why?
|
| Immunoprecipitation | 2 | 2014 | 126 | 0.140 |
Why?
|
| HEK293 Cells | 3 | 2015 | 618 | 0.140 |
Why?
|
| Poly I-C | 6 | 2009 | 76 | 0.140 |
Why?
|
| Fluorescent Antibody Technique | 7 | 2020 | 233 | 0.140 |
Why?
|
| Triazoles | 2 | 2014 | 56 | 0.140 |
Why?
|
| Bronchial Hyperreactivity | 3 | 2006 | 25 | 0.140 |
Why?
|
| Pulmonary Fibrosis | 1 | 1997 | 79 | 0.140 |
Why?
|
| Adenosine Triphosphatases | 2 | 2018 | 257 | 0.140 |
Why?
|
| MicroRNAs | 2 | 2021 | 680 | 0.140 |
Why?
|
| Ear | 1 | 2017 | 10 | 0.140 |
Why?
|
| Omentum | 1 | 1997 | 13 | 0.140 |
Why?
|
| Molecular Sequence Data | 13 | 2013 | 1997 | 0.140 |
Why?
|
| Immunity | 3 | 2020 | 107 | 0.130 |
Why?
|
| Homeostasis | 2 | 2017 | 368 | 0.130 |
Why?
|
| Respiratory Hypersensitivity | 3 | 2001 | 11 | 0.130 |
Why?
|
| STAT3 Transcription Factor | 2 | 2015 | 70 | 0.130 |
Why?
|
| Histocytochemistry | 3 | 2012 | 47 | 0.130 |
Why?
|
| Carotid Artery Injuries | 1 | 2016 | 13 | 0.130 |
Why?
|
| Leukemia Virus, Murine | 3 | 2015 | 30 | 0.130 |
Why?
|
| HLA-B27 Antigen | 1 | 2016 | 3 | 0.130 |
Why?
|
| Rituximab | 1 | 2017 | 84 | 0.130 |
Why?
|
| Receptors, KIR3DL1 | 1 | 2016 | 6 | 0.130 |
Why?
|
| Models, Genetic | 1 | 2018 | 260 | 0.130 |
Why?
|
| COS Cells | 2 | 2014 | 174 | 0.130 |
Why?
|
| Leukemia, T-Cell | 1 | 1996 | 5 | 0.130 |
Why?
|
| alpha 1-Antitrypsin | 1 | 2017 | 88 | 0.130 |
Why?
|
| DNA Repair | 4 | 2011 | 246 | 0.130 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 1 | 2017 | 63 | 0.130 |
Why?
|
| Vascular System Injuries | 1 | 2016 | 21 | 0.130 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2016 | 62 | 0.130 |
Why?
|
| MafB Transcription Factor | 1 | 2016 | 5 | 0.130 |
Why?
|
| Recombinant Proteins | 9 | 2010 | 700 | 0.130 |
Why?
|
| Passive Cutaneous Anaphylaxis | 1 | 2016 | 6 | 0.130 |
Why?
|
| Chimerism | 3 | 2016 | 11 | 0.130 |
Why?
|
| Diabetes Mellitus | 5 | 2020 | 536 | 0.130 |
Why?
|
| Drug Resistance, Multiple | 1 | 2016 | 34 | 0.130 |
Why?
|
| Immunoblotting | 2 | 2014 | 204 | 0.130 |
Why?
|
| Up-Regulation | 4 | 2013 | 375 | 0.130 |
Why?
|
| Self Tolerance | 1 | 2016 | 20 | 0.130 |
Why?
|
| Injections, Intravenous | 6 | 2020 | 156 | 0.130 |
Why?
|
| Virulence | 5 | 2022 | 195 | 0.130 |
Why?
|
| Mutagenesis | 2 | 2014 | 133 | 0.130 |
Why?
|
| Coculture Techniques | 4 | 2020 | 97 | 0.120 |
Why?
|
| Polymerase Chain Reaction | 10 | 2008 | 516 | 0.120 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 1 | 1 | 2015 | 6 | 0.120 |
Why?
|
| Chromosome Aberrations | 3 | 1992 | 68 | 0.120 |
Why?
|
| Retroviridae Infections | 1 | 2015 | 13 | 0.120 |
Why?
|
| Hematologic Neoplasms | 1 | 2016 | 49 | 0.120 |
Why?
|
| Salmonella typhimurium | 1 | 2016 | 86 | 0.120 |
Why?
|
| Fusion Proteins, bcr-abl | 2 | 2013 | 35 | 0.120 |
Why?
|
| Femoral Artery | 1 | 2016 | 110 | 0.120 |
Why?
|
| Neurons | 3 | 2013 | 919 | 0.120 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2016 | 60 | 0.120 |
Why?
|
| Muscle, Skeletal | 3 | 2015 | 734 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2014 | 418 | 0.120 |
Why?
|
| Mice, Hairless | 5 | 1990 | 18 | 0.120 |
Why?
|
| Forkhead Transcription Factors | 1 | 2016 | 129 | 0.120 |
Why?
|
| Pancreatic Neoplasms | 1 | 2018 | 339 | 0.120 |
Why?
|
| Receptors, Bombesin | 2 | 2006 | 2 | 0.120 |
Why?
|
| Osteoblasts | 3 | 2008 | 198 | 0.120 |
Why?
|
| TNF Receptor-Associated Factor 1 | 1 | 2014 | 1 | 0.120 |
Why?
|
| Gene Transfer Techniques | 3 | 2012 | 315 | 0.120 |
Why?
|
| Blood Glucose | 5 | 2011 | 485 | 0.120 |
Why?
|
| Antibodies, Viral | 2 | 2014 | 321 | 0.120 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2013 | 298 | 0.120 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2015 | 57 | 0.120 |
Why?
|
| Cloning, Molecular | 3 | 2014 | 383 | 0.120 |
Why?
|
| Blood Transfusion | 4 | 2004 | 161 | 0.120 |
Why?
|
| Atherosclerosis | 1 | 2016 | 152 | 0.120 |
Why?
|
| Coxsackievirus Infections | 1 | 2014 | 12 | 0.120 |
Why?
|
| Mice, Inbred CBA | 8 | 2007 | 83 | 0.120 |
Why?
|
| Extracellular Matrix | 2 | 2015 | 139 | 0.120 |
Why?
|
| Muromegalovirus | 1 | 1994 | 7 | 0.120 |
Why?
|
| Virus Internalization | 1 | 2015 | 87 | 0.120 |
Why?
|
| ADP-ribosyl Cyclase 1 | 5 | 2008 | 28 | 0.120 |
Why?
|
| Chromatin | 2 | 2023 | 618 | 0.110 |
Why?
|
| Laminin | 1 | 2015 | 78 | 0.110 |
Why?
|
| Receptors, CCR5 | 2 | 2012 | 59 | 0.110 |
Why?
|
| Lentivirus | 1 | 2015 | 66 | 0.110 |
Why?
|
| Bowman Capsule | 1 | 2014 | 2 | 0.110 |
Why?
|
| Macrophage-1 Antigen | 2 | 1993 | 31 | 0.110 |
Why?
|
| Herpesviridae Infections | 1 | 1994 | 27 | 0.110 |
Why?
|
| EGF Family of Proteins | 1 | 2014 | 1 | 0.110 |
Why?
|
| RNA-Binding Proteins | 2 | 2015 | 434 | 0.110 |
Why?
|
| Amphiregulin | 1 | 2014 | 3 | 0.110 |
Why?
|
| Virus Replication | 2 | 2013 | 319 | 0.110 |
Why?
|
| Amyloid | 1 | 2015 | 69 | 0.110 |
Why?
|
| Hybridomas | 5 | 2010 | 64 | 0.110 |
Why?
|
| Organoids | 4 | 1997 | 43 | 0.110 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2015 | 66 | 0.110 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2014 | 58 | 0.110 |
Why?
|
| Integrin alpha6 | 1 | 2014 | 20 | 0.110 |
Why?
|
| Tissue Transplantation | 1 | 2014 | 9 | 0.110 |
Why?
|
| Antigens, CD19 | 3 | 2008 | 22 | 0.110 |
Why?
|
| Inclusion Bodies | 2 | 1991 | 14 | 0.110 |
Why?
|
| Lymphokines | 5 | 1989 | 66 | 0.110 |
Why?
|
| Age Factors | 7 | 2017 | 1556 | 0.110 |
Why?
|
| tat Gene Products, Human Immunodeficiency Virus | 1 | 2013 | 13 | 0.110 |
Why?
|
| Nuclear Proteins | 4 | 2014 | 775 | 0.110 |
Why?
|
| src Homology Domains | 3 | 2004 | 21 | 0.110 |
Why?
|
| Yttrium Radioisotopes | 1 | 2013 | 7 | 0.110 |
Why?
|
| Receptors, Tumor Necrosis Factor | 3 | 2009 | 63 | 0.110 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2014 | 207 | 0.110 |
Why?
|
| Induction Chemotherapy | 1 | 2014 | 41 | 0.110 |
Why?
|
| Mycobacterium bovis | 1 | 2013 | 28 | 0.110 |
Why?
|
| Myeloid Differentiation Factor 88 | 3 | 2009 | 204 | 0.110 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2014 | 77 | 0.110 |
Why?
|
| Metal Nanoparticles | 1 | 2016 | 186 | 0.110 |
Why?
|
| Antigens, Surface | 4 | 2011 | 196 | 0.110 |
Why?
|
| Plasmodium berghei | 1 | 2013 | 21 | 0.100 |
Why?
|
| Young Adult | 6 | 2020 | 4655 | 0.100 |
Why?
|
| DNA Primers | 5 | 2012 | 293 | 0.100 |
Why?
|
| Peyer's Patches | 2 | 2013 | 36 | 0.100 |
Why?
|
| Neuroprotective Agents | 1 | 2013 | 75 | 0.100 |
Why?
|
| Pyramidal Tracts | 1 | 2013 | 25 | 0.100 |
Why?
|
| Organ Culture Techniques | 5 | 2002 | 69 | 0.100 |
Why?
|
| Adenocarcinoma | 1 | 2016 | 337 | 0.100 |
Why?
|
| T-Cell Acute Lymphocytic Leukemia Protein 1 | 1 | 2013 | 22 | 0.100 |
Why?
|
| Autocrine Communication | 1 | 2013 | 31 | 0.100 |
Why?
|
| Gallbladder | 1 | 2013 | 37 | 0.100 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2013 | 97 | 0.100 |
Why?
|
| Mammary Glands, Animal | 2 | 2020 | 79 | 0.100 |
Why?
|
| Myofibrils | 1 | 2012 | 19 | 0.100 |
Why?
|
| Research | 1 | 2014 | 192 | 0.100 |
Why?
|
| Motor Cortex | 1 | 2013 | 72 | 0.100 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2013 | 39 | 0.100 |
Why?
|
| Cyclooxygenase 2 | 2 | 2023 | 76 | 0.100 |
Why?
|
| Neuropilin-2 | 1 | 2013 | 40 | 0.100 |
Why?
|
| beta Catenin | 1 | 2013 | 93 | 0.100 |
Why?
|
| Spectral Karyotyping | 1 | 2012 | 2 | 0.100 |
Why?
|
| Muscular Dystrophy, Animal | 1 | 2012 | 5 | 0.100 |
Why?
|
| Salivary Proteins and Peptides | 1 | 2012 | 6 | 0.100 |
Why?
|
| Sequence Analysis, DNA | 3 | 2017 | 413 | 0.100 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 2 | 2005 | 10 | 0.100 |
Why?
|
| Antigens, Neoplasm | 3 | 2013 | 137 | 0.100 |
Why?
|
| Immunoconjugates | 2 | 2006 | 90 | 0.100 |
Why?
|
| Insulin Resistance | 1 | 2015 | 410 | 0.100 |
Why?
|
| Receptors, Interleukin-4 | 3 | 2003 | 8 | 0.100 |
Why?
|
| Anti-HIV Agents | 1 | 2013 | 154 | 0.100 |
Why?
|
| Peptide Fragments | 3 | 2016 | 411 | 0.100 |
Why?
|
| Down-Regulation | 3 | 2016 | 318 | 0.100 |
Why?
|
| Specific Pathogen-Free Organisms | 6 | 2014 | 42 | 0.100 |
Why?
|
| Mucins | 1 | 2012 | 26 | 0.100 |
Why?
|
| Prostatic Neoplasms | 1 | 2016 | 397 | 0.100 |
Why?
|
| Acetates | 1 | 2012 | 32 | 0.100 |
Why?
|
| Fucose | 1 | 2012 | 5 | 0.100 |
Why?
|
| Immunocompromised Host | 2 | 2011 | 107 | 0.100 |
Why?
|
| Carcinogenesis | 3 | 2019 | 130 | 0.100 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 4 | 1999 | 119 | 0.100 |
Why?
|
| Clone Cells | 5 | 2017 | 114 | 0.090 |
Why?
|
| Regenerative Medicine | 1 | 2011 | 20 | 0.090 |
Why?
|
| Virus Latency | 1 | 2011 | 32 | 0.090 |
Why?
|
| Stem Cell Transplantation | 3 | 2009 | 78 | 0.090 |
Why?
|
| Fibroblasts | 5 | 2022 | 392 | 0.090 |
Why?
|
| Genetic Variation | 2 | 2012 | 385 | 0.090 |
Why?
|
| Erythrocytes | 4 | 2010 | 149 | 0.090 |
Why?
|
| Purkinje Cells | 1 | 2011 | 6 | 0.090 |
Why?
|
| Adult | 13 | 2020 | 16672 | 0.090 |
Why?
|
| Leukocyte Count | 4 | 2000 | 96 | 0.090 |
Why?
|
| Lipofuscin | 1 | 2011 | 5 | 0.090 |
Why?
|
| Recovery of Function | 1 | 2013 | 282 | 0.090 |
Why?
|
| Epidermis | 2 | 1997 | 37 | 0.090 |
Why?
|
| Malaria, Falciparum | 2 | 2009 | 220 | 0.090 |
Why?
|
| Ceramides | 1 | 2011 | 25 | 0.090 |
Why?
|
| Mice, Inbred A | 2 | 2009 | 20 | 0.090 |
Why?
|
| Brain Injuries | 1 | 2013 | 140 | 0.090 |
Why?
|
| Pancreatic Ducts | 1 | 2011 | 30 | 0.090 |
Why?
|
| Phagocytosis | 3 | 2012 | 264 | 0.090 |
Why?
|
| Megakaryocytes | 2 | 2009 | 18 | 0.090 |
Why?
|
| Arthritis | 1 | 1991 | 53 | 0.090 |
Why?
|
| Receptor, Interferon alpha-beta | 2 | 2009 | 54 | 0.090 |
Why?
|
| Nanoparticles | 2 | 2018 | 517 | 0.090 |
Why?
|
| Cell Survival | 7 | 2016 | 573 | 0.090 |
Why?
|
| Gamma Rays | 4 | 2001 | 32 | 0.090 |
Why?
|
| Antigens, Helminth | 1 | 2010 | 9 | 0.090 |
Why?
|
| Morpholines | 1 | 2011 | 89 | 0.090 |
Why?
|
| Diphosphonates | 1 | 2010 | 34 | 0.090 |
Why?
|
| Cell Adhesion Molecules | 3 | 2001 | 89 | 0.090 |
Why?
|
| Kinetics | 5 | 2009 | 764 | 0.090 |
Why?
|
| Epigenesis, Genetic | 1 | 2014 | 384 | 0.090 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2012 | 173 | 0.090 |
Why?
|
| Radiography | 3 | 2002 | 538 | 0.090 |
Why?
|
| Imidazoles | 1 | 2010 | 80 | 0.080 |
Why?
|
| Skin Diseases, Papulosquamous | 3 | 1995 | 3 | 0.080 |
Why?
|
| Chromosomes | 1 | 1992 | 138 | 0.080 |
Why?
|
| Morbidity | 1 | 2010 | 113 | 0.080 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2010 | 36 | 0.080 |
Why?
|
| Drug Synergism | 4 | 2021 | 142 | 0.080 |
Why?
|
| Disease | 1 | 2010 | 27 | 0.080 |
Why?
|
| Chemotaxis | 2 | 2008 | 49 | 0.080 |
Why?
|
| Disease Susceptibility | 5 | 1995 | 166 | 0.080 |
Why?
|
| Perforin | 3 | 2005 | 31 | 0.080 |
Why?
|
| Tuberculosis | 1 | 2013 | 294 | 0.080 |
Why?
|
| Pore Forming Cytotoxic Proteins | 3 | 2005 | 34 | 0.080 |
Why?
|
| CD40 Antigens | 5 | 2006 | 61 | 0.080 |
Why?
|
| Bleeding Time | 1 | 2009 | 4 | 0.080 |
Why?
|
| Indoles | 3 | 2016 | 110 | 0.080 |
Why?
|
| Child | 6 | 2018 | 4477 | 0.080 |
Why?
|
| Piperazines | 1 | 2010 | 78 | 0.080 |
Why?
|
| Tetrahydrofolate Dehydrogenase | 1 | 2009 | 22 | 0.080 |
Why?
|
| Growth Inhibitors | 3 | 2006 | 26 | 0.080 |
Why?
|
| Leukemia | 1 | 2010 | 62 | 0.080 |
Why?
|
| Proteins | 3 | 2005 | 751 | 0.080 |
Why?
|
| Obesity | 2 | 2015 | 1230 | 0.080 |
Why?
|
| Antibodies, Neutralizing | 3 | 2018 | 207 | 0.080 |
Why?
|
| Graves Disease | 6 | 1997 | 16 | 0.080 |
Why?
|
| Endothelium, Vascular | 2 | 2003 | 175 | 0.080 |
Why?
|
| Disease Progression | 3 | 2020 | 1159 | 0.080 |
Why?
|
| Streptozocin | 2 | 1994 | 22 | 0.080 |
Why?
|
| Case-Control Studies | 3 | 2023 | 1115 | 0.080 |
Why?
|
| Respiratory Syncytial Virus Infections | 2 | 2000 | 34 | 0.080 |
Why?
|
| RNA Interference | 2 | 2014 | 619 | 0.080 |
Why?
|
| Echocardiography | 1 | 2012 | 498 | 0.080 |
Why?
|
| Galactosylceramides | 1 | 2009 | 11 | 0.080 |
Why?
|
| Interferon Type I | 2 | 2009 | 186 | 0.080 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2009 | 135 | 0.080 |
Why?
|
| Methotrexate | 1 | 2009 | 80 | 0.080 |
Why?
|
| Immunologic Memory | 2 | 2008 | 290 | 0.080 |
Why?
|
| Chemotactic Factors | 1 | 1989 | 26 | 0.080 |
Why?
|
| Promoter Regions, Genetic | 1 | 2012 | 672 | 0.080 |
Why?
|
| Repressor Proteins | 2 | 2014 | 348 | 0.080 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2009 | 44 | 0.080 |
Why?
|
| Janus Kinases | 1 | 2008 | 17 | 0.080 |
Why?
|
| Antigens, Differentiation | 6 | 1999 | 138 | 0.080 |
Why?
|
| Granulocytes | 3 | 2002 | 71 | 0.080 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 1989 | 62 | 0.080 |
Why?
|
| Listeriosis | 1 | 2008 | 30 | 0.070 |
Why?
|
| Respiratory Burst | 1 | 2008 | 21 | 0.070 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2008 | 6 | 0.070 |
Why?
|
| In Situ Hybridization | 5 | 2001 | 218 | 0.070 |
Why?
|
| Disease Outbreaks | 1 | 1989 | 115 | 0.070 |
Why?
|
| Macrophages, Peritoneal | 2 | 1998 | 77 | 0.070 |
Why?
|
| Growth Substances | 2 | 1985 | 34 | 0.070 |
Why?
|
| Endothelial Cells | 1 | 2009 | 185 | 0.070 |
Why?
|
| Fibrosarcoma | 1 | 1988 | 13 | 0.070 |
Why?
|
| K562 Cells | 2 | 2020 | 57 | 0.070 |
Why?
|
| Iron | 3 | 2019 | 146 | 0.070 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2008 | 171 | 0.070 |
Why?
|
| Hair | 3 | 2003 | 83 | 0.070 |
Why?
|
| Staining and Labeling | 3 | 2011 | 126 | 0.070 |
Why?
|
| CD4-CD8 Ratio | 3 | 2003 | 16 | 0.070 |
Why?
|
| Glioma | 1 | 2008 | 100 | 0.070 |
Why?
|
| Treatment Outcome | 5 | 2023 | 5596 | 0.070 |
Why?
|
| Lymphoid Progenitor Cells | 1 | 2007 | 6 | 0.070 |
Why?
|
| Myeloid Progenitor Cells | 1 | 2007 | 12 | 0.070 |
Why?
|
| Liver Transplantation | 6 | 2016 | 215 | 0.070 |
Why?
|
| Mice, Inbred DBA | 6 | 2003 | 84 | 0.070 |
Why?
|
| Chemokine CCL2 | 1 | 2007 | 56 | 0.070 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2006 | 125 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2008 | 203 | 0.070 |
Why?
|
| Hemolysis | 2 | 1998 | 40 | 0.070 |
Why?
|
| Small Molecule Libraries | 2 | 2020 | 58 | 0.070 |
Why?
|
| Receptors, Cell Surface | 2 | 2014 | 431 | 0.070 |
Why?
|
| CD8 Antigens | 6 | 2003 | 54 | 0.070 |
Why?
|
| Th2 Cells | 5 | 2007 | 98 | 0.070 |
Why?
|
| Molecular Targeted Therapy | 2 | 2018 | 129 | 0.070 |
Why?
|
| Muridae | 2 | 1996 | 8 | 0.060 |
Why?
|
| Protein Phosphatase 1 | 3 | 2005 | 16 | 0.060 |
Why?
|
| Polymorphism, Restriction Fragment Length | 2 | 1996 | 26 | 0.060 |
Why?
|
| Immunoglobulin Class Switching | 2 | 2004 | 83 | 0.060 |
Why?
|
| Receptors, Leukotriene B4 | 1 | 2006 | 2 | 0.060 |
Why?
|
| Ophthalmoscopy | 1 | 2006 | 3 | 0.060 |
Why?
|
| Leukotriene B4 | 1 | 2006 | 12 | 0.060 |
Why?
|
| Receptors, Purinergic P2 | 1 | 2006 | 9 | 0.060 |
Why?
|
| Heterozygote | 5 | 2013 | 168 | 0.060 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2006 | 37 | 0.060 |
Why?
|
| Photoreceptor Cells, Vertebrate | 1 | 2006 | 15 | 0.060 |
Why?
|
| Graft Enhancement, Immunologic | 1 | 2006 | 10 | 0.060 |
Why?
|
| Carcinoma, Small Cell | 1 | 2006 | 22 | 0.060 |
Why?
|
| Electroretinography | 1 | 2006 | 26 | 0.060 |
Why?
|
| Keratins | 1 | 2006 | 31 | 0.060 |
Why?
|
| Transcription, Genetic | 7 | 2013 | 875 | 0.060 |
Why?
|
| Sodium Hydroxide | 1 | 2005 | 2 | 0.060 |
Why?
|
| Suppressor of Cytokine Signaling 1 Protein | 1 | 2005 | 5 | 0.060 |
Why?
|
| Mammary Tumor Virus, Mouse | 1 | 1985 | 7 | 0.060 |
Why?
|
| Emphysema | 1 | 2006 | 39 | 0.060 |
Why?
|
| Epithelium, Corneal | 1 | 2005 | 6 | 0.060 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2005 | 9 | 0.060 |
Why?
|
| Collagenases | 1 | 2005 | 16 | 0.060 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2005 | 14 | 0.060 |
Why?
|
| Stomach | 2 | 1997 | 86 | 0.060 |
Why?
|
| Matrix Metalloproteinases | 1 | 2005 | 16 | 0.060 |
Why?
|
| Antibody Specificity | 2 | 2012 | 103 | 0.060 |
Why?
|
| Middle Aged | 9 | 2020 | 17391 | 0.060 |
Why?
|
| Cell Adhesion | 6 | 2003 | 207 | 0.060 |
Why?
|
| Tissue Distribution | 4 | 2009 | 293 | 0.060 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2009 | 667 | 0.060 |
Why?
|
| Anemia | 3 | 2005 | 127 | 0.060 |
Why?
|
| Genomics | 2 | 2020 | 368 | 0.060 |
Why?
|
| Myocytes, Cardiac | 1 | 2006 | 96 | 0.060 |
Why?
|
| RNA | 4 | 2009 | 422 | 0.060 |
Why?
|
| Thymus Neoplasms | 3 | 1995 | 22 | 0.060 |
Why?
|
| Genotype | 3 | 2003 | 666 | 0.060 |
Why?
|
| Morphogenesis | 1 | 2006 | 112 | 0.060 |
Why?
|
| Brain Neoplasms | 1 | 2008 | 308 | 0.060 |
Why?
|
| Adolescent | 4 | 2020 | 6195 | 0.060 |
Why?
|
| CD3 Complex | 5 | 2014 | 65 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinase 9 | 1 | 2005 | 45 | 0.060 |
Why?
|
| Large Neutral Amino Acid-Transporter 1 | 1 | 2024 | 2 | 0.060 |
Why?
|
| Receptors, Glucagon | 1 | 2024 | 4 | 0.060 |
Why?
|
| Immune Reconstitution | 1 | 2024 | 1 | 0.060 |
Why?
|
| Basophils | 2 | 2019 | 14 | 0.060 |
Why?
|
| Recombinant Fusion Proteins | 6 | 2009 | 495 | 0.060 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 2 | 2015 | 32 | 0.060 |
Why?
|
| Peptides | 3 | 2017 | 576 | 0.060 |
Why?
|
| Antibodies, Helminth | 5 | 2010 | 10 | 0.060 |
Why?
|
| CD24 Antigen | 2 | 2014 | 18 | 0.060 |
Why?
|
| Antigens, T-Independent | 1 | 2004 | 10 | 0.060 |
Why?
|
| Infant, Newborn | 5 | 2008 | 1348 | 0.060 |
Why?
|
| Fetal Tissue Transplantation | 2 | 2012 | 12 | 0.060 |
Why?
|
| HLA-DR4 Antigen | 2 | 2016 | 9 | 0.060 |
Why?
|
| Ligands | 4 | 2015 | 417 | 0.060 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2024 | 51 | 0.060 |
Why?
|
| CD4 Antigens | 5 | 2003 | 149 | 0.060 |
Why?
|
| Lymphoproliferative Disorders | 3 | 2001 | 39 | 0.060 |
Why?
|
| Interleukin-13 | 3 | 2014 | 37 | 0.060 |
Why?
|
| NIMA-Related Kinases | 1 | 2024 | 5 | 0.060 |
Why?
|
| Actins | 1 | 2006 | 259 | 0.060 |
Why?
|
| Larva | 3 | 2010 | 137 | 0.060 |
Why?
|
| Bortezomib | 1 | 2024 | 56 | 0.050 |
Why?
|
| Microscopy, Immunoelectron | 3 | 2000 | 31 | 0.050 |
Why?
|
| Lymphopenia | 2 | 2003 | 35 | 0.050 |
Why?
|
| Ascitic Fluid | 1 | 2003 | 12 | 0.050 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2004 | 41 | 0.050 |
Why?
|
| Nuclear Envelope | 1 | 2004 | 49 | 0.050 |
Why?
|
| Blood Cells | 1 | 2003 | 17 | 0.050 |
Why?
|
| Immunoenzyme Techniques | 4 | 1997 | 108 | 0.050 |
Why?
|
| Breeding | 1 | 2003 | 26 | 0.050 |
Why?
|
| Recurrence | 3 | 2014 | 636 | 0.050 |
Why?
|
| Adipose Tissue | 1 | 2006 | 296 | 0.050 |
Why?
|
| Child, Preschool | 3 | 2016 | 1962 | 0.050 |
Why?
|
| Lymphocyte Subsets | 4 | 1996 | 37 | 0.050 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 1 | 2024 | 33 | 0.050 |
Why?
|
| Clodronic Acid | 2 | 2008 | 4 | 0.050 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 2 | 2016 | 25 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2016 | 205 | 0.050 |
Why?
|
| CD56 Antigen | 2 | 2019 | 17 | 0.050 |
Why?
|
| Foreign-Body Reaction | 1 | 2023 | 16 | 0.050 |
Why?
|
| Leukocytes | 3 | 2003 | 104 | 0.050 |
Why?
|
| Prediabetic State | 2 | 1995 | 53 | 0.050 |
Why?
|
| Tissue Donors | 3 | 2018 | 153 | 0.050 |
Why?
|
| Osmotic Fragility | 1 | 2003 | 1 | 0.050 |
Why?
|
| Immunosuppressive Agents | 2 | 2020 | 377 | 0.050 |
Why?
|
| Prognosis | 3 | 2015 | 1727 | 0.050 |
Why?
|
| Heterochromatin | 1 | 2004 | 87 | 0.050 |
Why?
|
| Gene Silencing | 2 | 2017 | 392 | 0.050 |
Why?
|
| Membrane Lipids | 1 | 2003 | 27 | 0.050 |
Why?
|
| Epithelium | 6 | 2002 | 95 | 0.050 |
Why?
|
| Erythrocyte Membrane | 1 | 2003 | 23 | 0.050 |
Why?
|
| Genes, Regulator | 1 | 2003 | 28 | 0.050 |
Why?
|
| Lipid Peroxidation | 1 | 2003 | 65 | 0.050 |
Why?
|
| Liposomes | 2 | 2008 | 106 | 0.050 |
Why?
|
| Receptors, Prostaglandin E, EP4 Subtype | 1 | 2022 | 5 | 0.050 |
Why?
|
| Anthraquinones | 1 | 2002 | 4 | 0.050 |
Why?
|
| Viral Load | 2 | 2014 | 231 | 0.050 |
Why?
|
| Cell Death | 3 | 2016 | 284 | 0.050 |
Why?
|
| Paclitaxel | 2 | 2018 | 100 | 0.050 |
Why?
|
| Research Personnel | 1 | 2023 | 94 | 0.050 |
Why?
|
| Histamine | 1 | 1982 | 21 | 0.050 |
Why?
|
| Intestinal Mucosa | 1 | 2004 | 244 | 0.050 |
Why?
|
| Listeria monocytogenes | 2 | 1973 | 34 | 0.050 |
Why?
|
| Blood Bactericidal Activity | 2 | 1973 | 66 | 0.050 |
Why?
|
| Alkaline Phosphatase | 1 | 2002 | 46 | 0.050 |
Why?
|
| Molting | 1 | 2002 | 9 | 0.050 |
Why?
|
| Collagen | 1 | 2003 | 127 | 0.050 |
Why?
|
| Brain Chemistry | 1 | 1982 | 76 | 0.050 |
Why?
|
| Acute Disease | 3 | 2019 | 671 | 0.050 |
Why?
|
| Brugia | 2 | 1992 | 4 | 0.050 |
Why?
|
| Cyclodextrins | 1 | 2002 | 13 | 0.050 |
Why?
|
| Oxidation-Reduction | 1 | 2003 | 325 | 0.050 |
Why?
|
| beta-Cyclodextrins | 1 | 2002 | 21 | 0.050 |
Why?
|
| Antigens, Ly | 3 | 1997 | 42 | 0.050 |
Why?
|
| Organ Specificity | 3 | 2018 | 193 | 0.050 |
Why?
|
| Proteinuria | 2 | 1999 | 41 | 0.050 |
Why?
|
| Infant | 3 | 2014 | 1623 | 0.050 |
Why?
|
| Vagina | 1 | 2002 | 82 | 0.050 |
Why?
|
| Recombination, Genetic | 2 | 1996 | 245 | 0.050 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2001 | 47 | 0.050 |
Why?
|
| Allergens | 1 | 2001 | 52 | 0.050 |
Why?
|
| Excipients | 1 | 2002 | 49 | 0.050 |
Why?
|
| fas Receptor | 1 | 2001 | 57 | 0.050 |
Why?
|
| Anemia, Hypochromic | 2 | 1995 | 5 | 0.050 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2021 | 8 | 0.050 |
Why?
|
| Hyperplasia | 3 | 1995 | 87 | 0.050 |
Why?
|
| Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2018 | 8 | 0.040 |
Why?
|
| Chemokine CXCL2 | 1 | 2000 | 14 | 0.040 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2001 | 11 | 0.040 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2000 | 35 | 0.040 |
Why?
|
| Lymphocyte Transfusion | 3 | 2003 | 37 | 0.040 |
Why?
|
| Granzymes | 1 | 2020 | 21 | 0.040 |
Why?
|
| Antibodies, Blocking | 1 | 2000 | 39 | 0.040 |
Why?
|
| Steroids | 1 | 2021 | 54 | 0.040 |
Why?
|
| Statistics, Nonparametric | 2 | 2012 | 213 | 0.040 |
Why?
|
| Colitis, Ulcerative | 1 | 2021 | 74 | 0.040 |
Why?
|
| Testis | 2 | 1997 | 141 | 0.040 |
Why?
|
| DNA Replication | 3 | 1995 | 234 | 0.040 |
Why?
|
| Interleukin-8 | 1 | 2000 | 88 | 0.040 |
Why?
|
| Receptors, Lipoprotein | 1 | 2000 | 1 | 0.040 |
Why?
|
| Plant Lectins | 1 | 2000 | 7 | 0.040 |
Why?
|
| Immunoglobulin Variable Region | 4 | 2008 | 34 | 0.040 |
Why?
|
| Combined Modality Therapy | 3 | 2004 | 369 | 0.040 |
Why?
|
| Epitopes | 2 | 2012 | 296 | 0.040 |
Why?
|
| Primary Cell Culture | 1 | 2020 | 78 | 0.040 |
Why?
|
| Hair Diseases | 1 | 2000 | 6 | 0.040 |
Why?
|
| Adaptation, Biological | 1 | 2020 | 18 | 0.040 |
Why?
|
| ADP-ribosyl Cyclase | 4 | 2005 | 6 | 0.040 |
Why?
|
| Mannose-Binding Lectins | 1 | 2000 | 22 | 0.040 |
Why?
|
| Sex Factors | 2 | 2017 | 975 | 0.040 |
Why?
|
| Mice, Obese | 2 | 2019 | 80 | 0.040 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2021 | 150 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2014 | 169 | 0.040 |
Why?
|
| Erythrocyte Count | 1 | 2000 | 15 | 0.040 |
Why?
|
| Cell Engineering | 1 | 2020 | 2 | 0.040 |
Why?
|
| Chemokines | 1 | 2000 | 95 | 0.040 |
Why?
|
| Pregnancy | 4 | 2020 | 2326 | 0.040 |
Why?
|
| Lipids | 1 | 2022 | 316 | 0.040 |
Why?
|
| Amino Acid Sequence | 5 | 2007 | 1595 | 0.040 |
Why?
|
| Nitric Oxide Synthase | 2 | 1998 | 47 | 0.040 |
Why?
|
| Kidney Glomerulus | 2 | 1997 | 22 | 0.040 |
Why?
|
| Thymidine | 2 | 2003 | 25 | 0.040 |
Why?
|
| Crohn Disease | 1 | 2021 | 111 | 0.040 |
Why?
|
| Lupus Vulgaris | 1 | 1999 | 3 | 0.040 |
Why?
|
| GATA1 Transcription Factor | 1 | 2019 | 7 | 0.040 |
Why?
|
| Colony-Stimulating Factors | 2 | 1990 | 5 | 0.040 |
Why?
|
| alpha 1-Antichymotrypsin | 1 | 1999 | 1 | 0.040 |
Why?
|
| Ovalbumin | 4 | 2001 | 116 | 0.040 |
Why?
|
| DNA-Activated Protein Kinase | 1 | 2019 | 12 | 0.040 |
Why?
|
| Genomic Islands | 1 | 2019 | 8 | 0.040 |
Why?
|
| Siderophores | 1 | 2019 | 11 | 0.040 |
Why?
|
| CTLA-4 Antigen | 2 | 2016 | 70 | 0.040 |
Why?
|
| Amino Acids, Aromatic | 1 | 2019 | 7 | 0.040 |
Why?
|
| THP-1 Cells | 1 | 2019 | 20 | 0.040 |
Why?
|
| Dentin | 1 | 1999 | 5 | 0.040 |
Why?
|
| Electroporation | 1 | 2019 | 35 | 0.040 |
Why?
|
| Receptors, Interleukin-6 | 1 | 1999 | 15 | 0.040 |
Why?
|
| Tomography | 1 | 1999 | 7 | 0.040 |
Why?
|
| Endocytosis | 1 | 2020 | 152 | 0.040 |
Why?
|
| Treatment Failure | 2 | 2014 | 199 | 0.040 |
Why?
|
| STAT6 Transcription Factor | 3 | 2004 | 7 | 0.040 |
Why?
|
| Plant Proteins | 1 | 2000 | 86 | 0.040 |
Why?
|
| Mice, Neurologic Mutants | 3 | 2001 | 14 | 0.040 |
Why?
|
| Pneumocystis | 2 | 1989 | 2 | 0.040 |
Why?
|
| Hematopoietic System | 2 | 2006 | 10 | 0.040 |
Why?
|
| Hybridization, Genetic | 2 | 1991 | 14 | 0.040 |
Why?
|
| Femur | 1 | 1999 | 53 | 0.040 |
Why?
|
| Bone Density Conservation Agents | 2 | 2010 | 46 | 0.040 |
Why?
|
| Bacterial Toxins | 1 | 2019 | 61 | 0.040 |
Why?
|
| Chemokines, CXC | 1 | 1999 | 29 | 0.040 |
Why?
|
| Receptors, CXCR4 | 1 | 1999 | 36 | 0.040 |
Why?
|
| Cell Cycle Proteins | 2 | 2014 | 396 | 0.040 |
Why?
|
| RNA, Viral | 2 | 2012 | 275 | 0.040 |
Why?
|
| G-Quadruplexes | 1 | 1998 | 6 | 0.040 |
Why?
|
| Theranostic Nanomedicine | 1 | 2018 | 8 | 0.040 |
Why?
|
| Binding Sites, Antibody | 1 | 1998 | 23 | 0.040 |
Why?
|
| Antigen Presentation | 2 | 2003 | 235 | 0.040 |
Why?
|
| Antibody Affinity | 1 | 1998 | 19 | 0.040 |
Why?
|
| N-Acetylneuraminic Acid | 1 | 2019 | 54 | 0.040 |
Why?
|
| Nucleic Acid Heteroduplexes | 1 | 1998 | 15 | 0.040 |
Why?
|
| Congresses as Topic | 1 | 2019 | 75 | 0.040 |
Why?
|
| Lupus Nephritis | 1 | 1999 | 34 | 0.040 |
Why?
|
| Neutralization Tests | 1 | 2018 | 122 | 0.040 |
Why?
|
| Medical Oncology | 1 | 2019 | 66 | 0.040 |
Why?
|
| Receptors, Cholinergic | 1 | 1998 | 20 | 0.040 |
Why?
|
| src-Family Kinases | 1 | 1998 | 63 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2010 | 863 | 0.040 |
Why?
|
| Advisory Committees | 1 | 2019 | 112 | 0.040 |
Why?
|
| Plasma Substitutes | 1 | 1998 | 5 | 0.040 |
Why?
|
| Diethylcarbamazine | 1 | 1998 | 2 | 0.040 |
Why?
|
| Filaricides | 1 | 1998 | 2 | 0.040 |
Why?
|
| Receptor, Macrophage Colony-Stimulating Factor | 1 | 1998 | 10 | 0.040 |
Why?
|
| Isotonic Solutions | 1 | 1998 | 14 | 0.040 |
Why?
|
| Papilloma | 1 | 1998 | 12 | 0.040 |
Why?
|
| Skin Pigmentation | 1 | 1998 | 33 | 0.040 |
Why?
|
| Body Weight | 3 | 2003 | 377 | 0.040 |
Why?
|
| Mitochondria | 2 | 2017 | 370 | 0.040 |
Why?
|
| Cellular Reprogramming | 1 | 2018 | 37 | 0.040 |
Why?
|
| Animals, Genetically Modified | 1 | 2018 | 289 | 0.040 |
Why?
|
| Cyclin A1 | 1 | 2017 | 3 | 0.040 |
Why?
|
| Abnormalities, Multiple | 1 | 1998 | 54 | 0.040 |
Why?
|
| Forkhead Box Protein M1 | 1 | 2017 | 6 | 0.040 |
Why?
|
| Bleomycin | 3 | 1986 | 34 | 0.040 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2017 | 13 | 0.040 |
Why?
|
| NFATC Transcription Factors | 1 | 2017 | 20 | 0.040 |
Why?
|
| Venoms | 1 | 2017 | 11 | 0.040 |
Why?
|
| Organ Size | 3 | 1986 | 171 | 0.030 |
Why?
|
| Melanocytes | 1 | 1998 | 80 | 0.030 |
Why?
|
| Regression Analysis | 1 | 1998 | 497 | 0.030 |
Why?
|
| DNA, Complementary | 2 | 2012 | 166 | 0.030 |
Why?
|
| Fucosyltransferases | 1 | 2017 | 4 | 0.030 |
Why?
|
| DNA, Viral | 2 | 1995 | 232 | 0.030 |
Why?
|
| E-Selectin | 1 | 2017 | 18 | 0.030 |
Why?
|
| Macrophages, Alveolar | 1 | 1997 | 64 | 0.030 |
Why?
|
| Zinc | 1 | 1998 | 92 | 0.030 |
Why?
|
| beta-Galactosidase | 1 | 1997 | 77 | 0.030 |
Why?
|
| Retroviridae | 1 | 1997 | 73 | 0.030 |
Why?
|
| Receptors, Granulocyte Colony-Stimulating Factor | 1 | 1997 | 1 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2014 | 303 | 0.030 |
Why?
|
| Thyrotropin | 2 | 1994 | 34 | 0.030 |
Why?
|
| Milk Proteins | 1 | 1997 | 44 | 0.030 |
Why?
|
| Epithelial Cells | 4 | 2006 | 390 | 0.030 |
Why?
|
| Haplotypes | 2 | 2011 | 131 | 0.030 |
Why?
|
| Cecum | 1 | 1997 | 16 | 0.030 |
Why?
|
| Leukocytosis | 1 | 1997 | 13 | 0.030 |
Why?
|
| Cell Communication | 2 | 1988 | 131 | 0.030 |
Why?
|
| Melanoma | 1 | 2020 | 331 | 0.030 |
Why?
|
| Microscopy, Electron, Scanning | 2 | 2000 | 107 | 0.030 |
Why?
|
| Parasitemia | 2 | 2013 | 47 | 0.030 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 1997 | 131 | 0.030 |
Why?
|
| Glycosylation | 1 | 2017 | 138 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2019 | 366 | 0.030 |
Why?
|
| Neointima | 1 | 2016 | 19 | 0.030 |
Why?
|
| Diethylamines | 1 | 1996 | 2 | 0.030 |
Why?
|
| Aedes | 1 | 1996 | 12 | 0.030 |
Why?
|
| Receptors, LDL | 1 | 2016 | 34 | 0.030 |
Why?
|
| Nitrogen Oxides | 1 | 1996 | 11 | 0.030 |
Why?
|
| Glutamate Decarboxylase | 1 | 2016 | 22 | 0.030 |
Why?
|
| Guanidines | 1 | 1996 | 13 | 0.030 |
Why?
|
| Extracellular Space | 1 | 2016 | 28 | 0.030 |
Why?
|
| Survival Rate | 1 | 2019 | 843 | 0.030 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 1996 | 20 | 0.030 |
Why?
|
| Single-Cell Analysis | 1 | 2017 | 113 | 0.030 |
Why?
|
| Binding Sites | 2 | 2011 | 902 | 0.030 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2016 | 33 | 0.030 |
Why?
|
| Cellular Senescence | 3 | 2004 | 110 | 0.030 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2017 | 102 | 0.030 |
Why?
|
| Thymectomy | 3 | 1999 | 34 | 0.030 |
Why?
|
| Tetradecanoylphorbol Acetate | 2 | 1999 | 66 | 0.030 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2016 | 60 | 0.030 |
Why?
|
| Apyrase | 2 | 1993 | 4 | 0.030 |
Why?
|
| National Institute of Allergy and Infectious Diseases (U.S.) | 1 | 2016 | 4 | 0.030 |
Why?
|
| HLA-DQ Antigens | 1 | 2016 | 14 | 0.030 |
Why?
|
| Receptors, Interleukin | 2 | 2006 | 38 | 0.030 |
Why?
|
| WT1 Proteins | 1 | 2015 | 6 | 0.030 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2016 | 33 | 0.030 |
Why?
|
| Ovulation | 1 | 1996 | 28 | 0.030 |
Why?
|
| Growth Hormone-Releasing Hormone | 1 | 1995 | 5 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2016 | 93 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2016 | 99 | 0.030 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 1996 | 101 | 0.030 |
Why?
|
| Growth Hormone | 1 | 1995 | 18 | 0.030 |
Why?
|
| Thyroiditis, Autoimmune | 2 | 1994 | 8 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2016 | 109 | 0.030 |
Why?
|
| Desmoglein 3 | 3 | 2001 | 6 | 0.030 |
Why?
|
| Glucose Clamp Technique | 1 | 2015 | 58 | 0.030 |
Why?
|
| Ovarian Follicle | 1 | 1996 | 40 | 0.030 |
Why?
|
| Bevacizumab | 1 | 2016 | 59 | 0.030 |
Why?
|
| Glucocorticoid-Induced TNFR-Related Protein | 1 | 2015 | 6 | 0.030 |
Why?
|
| Protein Conformation | 1 | 1998 | 776 | 0.030 |
Why?
|
| Dexamethasone | 2 | 1999 | 205 | 0.030 |
Why?
|
| Microfilament Proteins | 1 | 2016 | 111 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2019 | 749 | 0.030 |
Why?
|
| Host-Parasite Interactions | 3 | 2001 | 58 | 0.030 |
Why?
|
| H-2 Antigens | 1 | 1995 | 67 | 0.030 |
Why?
|
| Culicidae | 1 | 1995 | 12 | 0.030 |
Why?
|
| TYK2 Kinase | 1 | 2015 | 2 | 0.030 |
Why?
|
| Snail Family Transcription Factors | 1 | 2015 | 28 | 0.030 |
Why?
|
| Vesicular Transport Proteins | 1 | 1996 | 113 | 0.030 |
Why?
|
| Janus Kinase 1 | 1 | 2015 | 11 | 0.030 |
Why?
|
| Activating Transcription Factor 3 | 1 | 2015 | 7 | 0.030 |
Why?
|
| Mutant Chimeric Proteins | 1 | 2015 | 6 | 0.030 |
Why?
|
| Immunoglobulin Heavy Chains | 2 | 1993 | 46 | 0.030 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2015 | 20 | 0.030 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2016 | 77 | 0.030 |
Why?
|
| Glucose-6-Phosphatase | 1 | 2015 | 15 | 0.030 |
Why?
|
| Heat Shock Transcription Factors | 1 | 2015 | 12 | 0.030 |
Why?
|
| Iodide Peroxidase | 2 | 1992 | 23 | 0.030 |
Why?
|
| Cholesterol | 1 | 2016 | 259 | 0.030 |
Why?
|
| Positive Regulatory Domain I-Binding Factor 1 | 1 | 2014 | 8 | 0.030 |
Why?
|
| Agammaglobulinemia | 1 | 1995 | 9 | 0.030 |
Why?
|
| beta-Thalassemia | 1 | 1995 | 13 | 0.030 |
Why?
|
| Protein Aggregates | 1 | 2015 | 20 | 0.030 |
Why?
|
| Immunity, Maternally-Acquired | 1 | 1994 | 11 | 0.030 |
Why?
|
| Jurkat Cells | 1 | 2015 | 110 | 0.030 |
Why?
|
| Enterovirus B, Human | 1 | 2014 | 17 | 0.030 |
Why?
|
| Proteasome Inhibitors | 1 | 2014 | 31 | 0.030 |
Why?
|
| Triglycerides | 1 | 2016 | 244 | 0.030 |
Why?
|
| Dietary Fats | 1 | 2015 | 176 | 0.030 |
Why?
|
| Capsid Proteins | 1 | 2015 | 98 | 0.030 |
Why?
|
| Hypogonadism | 1 | 1994 | 13 | 0.030 |
Why?
|
| Diet, High-Fat | 1 | 2015 | 174 | 0.030 |
Why?
|
| Macaca mulatta | 1 | 2015 | 249 | 0.030 |
Why?
|
| Autoradiography | 1 | 1994 | 53 | 0.030 |
Why?
|
| Tritium | 1 | 1994 | 22 | 0.030 |
Why?
|
| Thyroid Diseases | 1 | 1994 | 26 | 0.030 |
Why?
|
| Lymphocytic Choriomeningitis | 1 | 1994 | 53 | 0.030 |
Why?
|
| Anemia, Sickle Cell | 1 | 1995 | 63 | 0.030 |
Why?
|
| Macrophage Activation | 1 | 1995 | 119 | 0.030 |
Why?
|
| Hyaluronan Receptors | 1 | 2014 | 35 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 1994 | 70 | 0.030 |
Why?
|
| Polycomb Repressive Complex 1 | 1 | 2014 | 31 | 0.030 |
Why?
|
| Lymphocytic choriomeningitis virus | 1 | 1994 | 89 | 0.030 |
Why?
|
| Lymphocyte Culture Test, Mixed | 2 | 2009 | 34 | 0.030 |
Why?
|
| Receptor Activator of Nuclear Factor-kappa B | 2 | 2004 | 5 | 0.030 |
Why?
|
| Fluorouracil | 1 | 2014 | 66 | 0.030 |
Why?
|
| Myeloproliferative Disorders | 1 | 1994 | 15 | 0.030 |
Why?
|
| RANK Ligand | 2 | 2004 | 22 | 0.030 |
Why?
|
| Polyomavirus | 1 | 1994 | 24 | 0.030 |
Why?
|
| Gold | 1 | 2016 | 226 | 0.030 |
Why?
|
| Green Fluorescent Proteins | 1 | 2015 | 364 | 0.030 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2014 | 42 | 0.030 |
Why?
|
| Oximes | 1 | 2013 | 11 | 0.030 |
Why?
|
| Tumor Virus Infections | 1 | 1994 | 36 | 0.030 |
Why?
|
| Proteome | 1 | 2015 | 149 | 0.030 |
Why?
|
| Rats, Inbred Lew | 3 | 2001 | 106 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2013 | 72 | 0.030 |
Why?
|
| Neoplasms, Experimental | 2 | 1992 | 77 | 0.030 |
Why?
|
| Polyomavirus Infections | 1 | 1994 | 45 | 0.030 |
Why?
|
| Estrogens | 1 | 1994 | 115 | 0.030 |
Why?
|
| Technetium | 1 | 2013 | 68 | 0.030 |
Why?
|
| Receptor, Notch1 | 1 | 2014 | 61 | 0.030 |
Why?
|
| Immunochemistry | 1 | 2013 | 10 | 0.030 |
Why?
|
| Injections | 1 | 2013 | 81 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-hck | 1 | 2013 | 1 | 0.030 |
Why?
|
| Testosterone | 1 | 1994 | 119 | 0.030 |
Why?
|
| Drug Interactions | 1 | 2013 | 127 | 0.030 |
Why?
|
| Forelimb | 1 | 2013 | 9 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 7 | 1 | 2013 | 11 | 0.030 |
Why?
|
| Bacteriolysis | 1 | 1973 | 6 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2014 | 146 | 0.030 |
Why?
|
| Zinc Finger Protein GLI1 | 1 | 2013 | 31 | 0.030 |
Why?
|
| Nerve Fibers | 1 | 2013 | 30 | 0.030 |
Why?
|
| Schizophrenia | 1 | 2015 | 267 | 0.030 |
Why?
|
| Karyotyping | 2 | 1998 | 47 | 0.030 |
Why?
|
| Skin Neoplasms | 1 | 1998 | 414 | 0.030 |
Why?
|
| Nerve Regeneration | 1 | 2013 | 36 | 0.030 |
Why?
|
| Cell Nucleus | 3 | 2008 | 623 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 2015 | 378 | 0.030 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 1993 | 247 | 0.030 |
Why?
|
| Estradiol | 1 | 1994 | 257 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2014 | 311 | 0.030 |
Why?
|
| Plasmodium falciparum | 1 | 1995 | 246 | 0.020 |
Why?
|
| Glucose | 1 | 2015 | 470 | 0.020 |
Why?
|
| Dengue Vaccines | 1 | 2012 | 8 | 0.020 |
Why?
|
| Mucin-4 | 1 | 2012 | 1 | 0.020 |
Why?
|
| Immunoglobulin Subunits | 1 | 2012 | 1 | 0.020 |
Why?
|
| Mucin 5AC | 1 | 2012 | 8 | 0.020 |
Why?
|
| Axons | 1 | 2013 | 123 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 1994 | 203 | 0.020 |
Why?
|
| Intestine, Small | 1 | 2013 | 79 | 0.020 |
Why?
|
| Goblet Cells | 1 | 2012 | 8 | 0.020 |
Why?
|
| Nasal Mucosa | 1 | 2012 | 18 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2014 | 670 | 0.020 |
Why?
|
| Immunity, Humoral | 1 | 2012 | 40 | 0.020 |
Why?
|
| Sulfides | 1 | 2012 | 22 | 0.020 |
Why?
|
| Indium Radioisotopes | 1 | 2012 | 41 | 0.020 |
Why?
|
| Cell Fusion | 2 | 2006 | 37 | 0.020 |
Why?
|
| Cyclopropanes | 1 | 2012 | 49 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 1992 | 52 | 0.020 |
Why?
|
| Virus Activation | 1 | 2011 | 24 | 0.020 |
Why?
|
| Isotope Labeling | 1 | 2012 | 70 | 0.020 |
Why?
|
| CA-125 Antigen | 1 | 2011 | 4 | 0.020 |
Why?
|
| Crystallography, X-Ray | 1 | 2013 | 432 | 0.020 |
Why?
|
| CCR5 Receptor Antagonists | 1 | 2011 | 16 | 0.020 |
Why?
|
| Cardiomegaly | 1 | 1991 | 34 | 0.020 |
Why?
|
| Antigens | 2 | 1993 | 147 | 0.020 |
Why?
|
| Mannosyl-Glycoprotein Endo-beta-N-Acetylglucosaminidase | 1 | 1991 | 1 | 0.020 |
Why?
|
| Acetylglucosaminidase | 1 | 1991 | 3 | 0.020 |
Why?
|
| Ascites | 1 | 2011 | 21 | 0.020 |
Why?
|
| Codon, Terminator | 1 | 2011 | 23 | 0.020 |
Why?
|
| Sphingosine N-Acyltransferase | 1 | 2011 | 1 | 0.020 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2011 | 95 | 0.020 |
Why?
|
| HeLa Cells | 2 | 2004 | 533 | 0.020 |
Why?
|
| Malaria | 1 | 2013 | 148 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2012 | 234 | 0.020 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 2011 | 6 | 0.020 |
Why?
|
| Immunoassay | 1 | 2011 | 70 | 0.020 |
Why?
|
| Rats, Inbred F344 | 1 | 2011 | 53 | 0.020 |
Why?
|
| Prealbumin | 1 | 2011 | 19 | 0.020 |
Why?
|
| Host-Pathogen Interactions | 1 | 2013 | 263 | 0.020 |
Why?
|
| Diacylglycerol Kinase | 1 | 2011 | 11 | 0.020 |
Why?
|
| Desmoglein 1 | 2 | 2001 | 2 | 0.020 |
Why?
|
| B7-2 Antigen | 2 | 2003 | 32 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2013 | 562 | 0.020 |
Why?
|
| Integumentary System | 1 | 2010 | 1 | 0.020 |
Why?
|
| Protein Prenylation | 1 | 2010 | 7 | 0.020 |
Why?
|
| Immunization | 3 | 2000 | 133 | 0.020 |
Why?
|
| Protein Binding | 3 | 2003 | 1606 | 0.020 |
Why?
|
| Interferons | 1 | 1991 | 74 | 0.020 |
Why?
|
| Everolimus | 1 | 2010 | 22 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2010 | 37 | 0.020 |
Why?
|
| Leukemia, B-Cell | 1 | 2010 | 6 | 0.020 |
Why?
|
| Splenomegaly | 1 | 2010 | 24 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2011 | 231 | 0.020 |
Why?
|
| Histones | 1 | 2014 | 482 | 0.020 |
Why?
|
| Blotting, Southern | 3 | 1997 | 55 | 0.020 |
Why?
|
| Fluorescent Dyes | 1 | 2012 | 198 | 0.020 |
Why?
|
| Imatinib Mesylate | 1 | 2010 | 34 | 0.020 |
Why?
|
| ras Proteins | 1 | 2010 | 77 | 0.020 |
Why?
|
| Gene Rearrangement, B-Lymphocyte, Heavy Chain | 2 | 2001 | 10 | 0.020 |
Why?
|
| Endoplasmic Reticulum | 1 | 1991 | 173 | 0.020 |
Why?
|
| Pituitary Gland, Anterior | 1 | 1990 | 30 | 0.020 |
Why?
|
| Tissue Survival | 1 | 2009 | 5 | 0.020 |
Why?
|
| Desmoplakins | 2 | 2001 | 9 | 0.020 |
Why?
|
| Benzamides | 1 | 2010 | 65 | 0.020 |
Why?
|
| Methacholine Chloride | 2 | 2000 | 23 | 0.020 |
Why?
|
| Acantholysis | 2 | 2000 | 5 | 0.020 |
Why?
|
| Receptors, Scavenger | 2 | 2000 | 9 | 0.020 |
Why?
|
| Computational Biology | 1 | 2012 | 354 | 0.020 |
Why?
|
| Pilot Projects | 1 | 1993 | 989 | 0.020 |
Why?
|
| Aged | 3 | 2014 | 14268 | 0.020 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2010 | 39 | 0.020 |
Why?
|
| Teratoma | 1 | 2009 | 13 | 0.020 |
Why?
|
| Luminescent Measurements | 1 | 2009 | 40 | 0.020 |
Why?
|
| Pyrimethamine | 1 | 2009 | 20 | 0.020 |
Why?
|
| SH2 Domain-Containing Protein Tyrosine Phosphatases | 2 | 2001 | 3 | 0.020 |
Why?
|
| Etanercept | 1 | 2009 | 32 | 0.020 |
Why?
|
| Chloroquine | 1 | 2009 | 61 | 0.020 |
Why?
|
| Oligopeptides | 1 | 2009 | 133 | 0.020 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 1 | 1989 | 5 | 0.020 |
Why?
|
| Erythroblasts | 1 | 1989 | 15 | 0.020 |
Why?
|
| Pyridones | 1 | 2009 | 40 | 0.020 |
Why?
|
| S100 Calcium-Binding Protein A4 | 1 | 2008 | 3 | 0.020 |
Why?
|
| S100 Calcium Binding Protein A6 | 1 | 2008 | 3 | 0.020 |
Why?
|
| Maine | 1 | 1989 | 18 | 0.020 |
Why?
|
| Artemisinins | 1 | 2009 | 38 | 0.020 |
Why?
|
| S100 Calcium Binding Protein beta Subunit | 1 | 2008 | 8 | 0.020 |
Why?
|
| Genes, Reporter | 2 | 2002 | 256 | 0.020 |
Why?
|
| Mice, Inbred ICR | 1 | 1989 | 32 | 0.020 |
Why?
|
| Michigan | 1 | 1989 | 43 | 0.020 |
Why?
|
| Drug Design | 1 | 2010 | 136 | 0.020 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 1989 | 10 | 0.020 |
Why?
|
| S100 Proteins | 1 | 2008 | 19 | 0.020 |
Why?
|
| Pennsylvania | 1 | 1989 | 64 | 0.020 |
Why?
|
| Blood Pressure | 1 | 1991 | 514 | 0.020 |
Why?
|
| Erythropoietin | 1 | 1989 | 39 | 0.020 |
Why?
|
| Nerve Growth Factors | 1 | 2008 | 27 | 0.020 |
Why?
|
| Ethylnitrosourea | 1 | 2008 | 11 | 0.020 |
Why?
|
| Culture Media, Conditioned | 1 | 2008 | 51 | 0.020 |
Why?
|
| Antigens, CD7 | 1 | 2008 | 2 | 0.020 |
Why?
|
| NAD+ Nucleosidase | 2 | 1999 | 10 | 0.020 |
Why?
|
| Immunoglobulin Fragments | 1 | 2008 | 7 | 0.020 |
Why?
|
| Intestines | 1 | 1990 | 166 | 0.020 |
Why?
|
| Dehydroepiandrosterone | 1 | 1988 | 13 | 0.020 |
Why?
|
| Lupus Erythematosus, Systemic | 2 | 2002 | 163 | 0.020 |
Why?
|
| Pneumococcal Vaccines | 1 | 2008 | 20 | 0.020 |
Why?
|
| Cell Nucleus Shape | 1 | 2008 | 5 | 0.020 |
Why?
|
| Drug Resistance | 1 | 2009 | 152 | 0.020 |
Why?
|
| Antigens, Fungal | 1 | 1989 | 57 | 0.020 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 1 | 2008 | 34 | 0.020 |
Why?
|
| Cytoskeletal Proteins | 2 | 2001 | 200 | 0.020 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2008 | 66 | 0.020 |
Why?
|
| Oligodeoxyribonucleotides | 2 | 2003 | 245 | 0.020 |
Why?
|
| Interferon Inducers | 1 | 2007 | 11 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 1988 | 79 | 0.020 |
Why?
|
| Toll-Like Receptor 3 | 1 | 2007 | 66 | 0.020 |
Why?
|
| Acid Phosphatase | 1 | 1987 | 8 | 0.020 |
Why?
|
| DNA Nucleotidylexotransferase | 1 | 1987 | 12 | 0.020 |
Why?
|
| Peritoneum | 1 | 2007 | 29 | 0.020 |
Why?
|
| Carboxylesterase | 1 | 1987 | 4 | 0.020 |
Why?
|
| Carboxylic Ester Hydrolases | 1 | 1987 | 11 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2008 | 182 | 0.020 |
Why?
|
| Endocrine Glands | 1 | 1987 | 6 | 0.020 |
Why?
|
| Cytoplasmic Granules | 1 | 1987 | 52 | 0.020 |
Why?
|
| Chromosome Disorders | 1 | 1987 | 14 | 0.020 |
Why?
|
| Hemolytic Plaque Technique | 4 | 1985 | 11 | 0.020 |
Why?
|
| Immunoglobulin Isotypes | 2 | 1999 | 24 | 0.020 |
Why?
|
| Guinea Pigs | 1 | 1987 | 84 | 0.020 |
Why?
|
| Glioblastoma | 1 | 2008 | 157 | 0.020 |
Why?
|
| X Chromosome | 1 | 1987 | 46 | 0.020 |
Why?
|
| 4-Nitroquinoline-1-oxide | 1 | 1986 | 3 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2007 | 258 | 0.020 |
Why?
|
| Melanins | 1 | 2006 | 24 | 0.020 |
Why?
|
| Environment | 1 | 1987 | 122 | 0.020 |
Why?
|
| Host vs Graft Reaction | 1 | 2006 | 3 | 0.020 |
Why?
|
| Subrenal Capsule Assay | 1 | 2006 | 3 | 0.020 |
Why?
|
| gamma-Globulins | 2 | 1996 | 10 | 0.020 |
Why?
|
| Muromonab-CD3 | 1 | 2006 | 7 | 0.020 |
Why?
|
| Antibody Diversity | 1 | 1986 | 8 | 0.020 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 2006 | 30 | 0.020 |
Why?
|
| Receptors, IgE | 1 | 2006 | 5 | 0.020 |
Why?
|
| Cattle | 2 | 1998 | 309 | 0.020 |
Why?
|
| Receptors, Interleukin-12 | 1 | 2006 | 9 | 0.020 |
Why?
|
| Clonal Deletion | 1 | 2006 | 11 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2006 | 30 | 0.020 |
Why?
|
| Graft vs Host Reaction | 2 | 1995 | 8 | 0.020 |
Why?
|
| Cycloheximide | 1 | 2005 | 21 | 0.020 |
Why?
|
| Interferon Regulatory Factor-1 | 1 | 2005 | 5 | 0.020 |
Why?
|
| Gastric Bypass | 1 | 2006 | 76 | 0.020 |
Why?
|
| Receptors, Lymphocyte Homing | 2 | 1999 | 15 | 0.020 |
Why?
|
| Oxytocin | 1 | 2006 | 45 | 0.020 |
Why?
|
| Anemia, Refractory, with Excess of Blasts | 1 | 2005 | 2 | 0.020 |
Why?
|
| T-Box Domain Proteins | 1 | 2005 | 38 | 0.020 |
Why?
|
| Leukemic Infiltration | 1 | 2005 | 5 | 0.020 |
Why?
|
| Chromosomes, Human | 1 | 2006 | 53 | 0.020 |
Why?
|
| Biological Transport | 1 | 2006 | 293 | 0.020 |
Why?
|
| Blood | 1 | 2005 | 30 | 0.020 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2005 | 60 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 1986 | 487 | 0.020 |
Why?
|
| Antibodies, Bispecific | 1 | 2006 | 31 | 0.020 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 1985 | 62 | 0.020 |
Why?
|
| DNA, Single-Stranded | 2 | 1999 | 106 | 0.020 |
Why?
|
| Metrizamide | 1 | 2004 | 4 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 2006 | 369 | 0.010 |
Why?
|
| Antigens, Viral | 1 | 1985 | 134 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2005 | 364 | 0.010 |
Why?
|
| Anemia, Macrocytic | 1 | 1984 | 1 | 0.010 |
Why?
|
| Mice, Inbred SENCAR | 1 | 2004 | 1 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2005 | 199 | 0.010 |
Why?
|
| Blotting, Northern | 2 | 1996 | 150 | 0.010 |
Why?
|
| Th1 Cells | 1 | 2005 | 175 | 0.010 |
Why?
|
| Rabbits | 3 | 1978 | 332 | 0.010 |
Why?
|
| Oncogene Proteins | 1 | 2004 | 33 | 0.010 |
Why?
|
| Osteoprotegerin | 1 | 2003 | 5 | 0.010 |
Why?
|
| Adjuvants, Immunologic | 1 | 1985 | 228 | 0.010 |
Why?
|
| Bombesin | 1 | 2003 | 2 | 0.010 |
Why?
|
| Etoposide | 1 | 2003 | 33 | 0.010 |
Why?
|
| Thyroglobulin | 2 | 1993 | 9 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2005 | 400 | 0.010 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2003 | 223 | 0.010 |
Why?
|
| Endostatins | 1 | 2003 | 3 | 0.010 |
Why?
|
| Cisplatin | 1 | 2003 | 140 | 0.010 |
Why?
|
| Models, Chemical | 1 | 2003 | 139 | 0.010 |
Why?
|
| United States | 1 | 2016 | 7744 | 0.010 |
Why?
|
| PAX7 Transcription Factor | 1 | 2002 | 9 | 0.010 |
Why?
|
| Founder Effect | 1 | 2002 | 11 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2002 | 23 | 0.010 |
Why?
|
| Microsatellite Repeats | 1 | 2002 | 41 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 2004 | 305 | 0.010 |
Why?
|
| Sweden | 1 | 2002 | 56 | 0.010 |
Why?
|
| Hypersensitivity | 1 | 2003 | 61 | 0.010 |
Why?
|
| Thyroxine | 2 | 1993 | 53 | 0.010 |
Why?
|
| Salivary Glands | 1 | 1982 | 46 | 0.010 |
Why?
|
| Bromodeoxyuridine | 1 | 2002 | 42 | 0.010 |
Why?
|
| 2-Hydroxypropyl-beta-cyclodextrin | 1 | 2002 | 6 | 0.010 |
Why?
|
| Pedigree | 1 | 2002 | 193 | 0.010 |
Why?
|
| S100 Calcium Binding Protein G | 1 | 2001 | 7 | 0.010 |
Why?
|
| Calbindins | 1 | 2001 | 10 | 0.010 |
Why?
|
| Administration, Topical | 1 | 2002 | 52 | 0.010 |
Why?
|
| Nasal Provocation Tests | 1 | 2001 | 1 | 0.010 |
Why?
|
| Epidermal Growth Factor | 2 | 1994 | 47 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2001 | 47 | 0.010 |
Why?
|
| Thy-1 Antigens | 2 | 1993 | 21 | 0.010 |
Why?
|
| Ataxia | 1 | 2001 | 23 | 0.010 |
Why?
|
| Genes, Immunoglobulin | 1 | 2001 | 34 | 0.010 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1982 | 52 | 0.010 |
Why?
|
| Regulatory Factor X Transcription Factors | 1 | 2001 | 15 | 0.010 |
Why?
|
| X-Box Binding Protein 1 | 1 | 2001 | 13 | 0.010 |
Why?
|
| Hydrocortisone | 1 | 1983 | 193 | 0.010 |
Why?
|
| Desmogleins | 1 | 2001 | 2 | 0.010 |
Why?
|
| Lichenoid Eruptions | 1 | 2001 | 2 | 0.010 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2001 | 47 | 0.010 |
Why?
|
| Progesterone | 1 | 2002 | 163 | 0.010 |
Why?
|
| Cerebellum | 1 | 2001 | 94 | 0.010 |
Why?
|
| Baculoviridae | 1 | 2000 | 25 | 0.010 |
Why?
|
| Permeability | 1 | 2001 | 49 | 0.010 |
Why?
|
| Head and Neck Neoplasms | 1 | 2002 | 167 | 0.010 |
Why?
|
| Intracellular Membranes | 1 | 2001 | 50 | 0.010 |
Why?
|
| Respiratory Mucosa | 1 | 2001 | 53 | 0.010 |
Why?
|
| Blister | 1 | 2000 | 17 | 0.010 |
Why?
|
| Pulmonary Eosinophilia | 1 | 2000 | 7 | 0.010 |
Why?
|
| Cerebral Cortex | 1 | 1982 | 258 | 0.010 |
Why?
|
| Scavenger Receptors, Class B | 1 | 2000 | 3 | 0.010 |
Why?
|
| Membrane Potentials | 1 | 2001 | 141 | 0.010 |
Why?
|
| Clonal Anergy | 1 | 2000 | 23 | 0.010 |
Why?
|
| Genes, fos | 1 | 2000 | 18 | 0.010 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2000 | 25 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 2000 | 99 | 0.010 |
Why?
|
| Radiation Dosage | 1 | 2001 | 134 | 0.010 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2001 | 149 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2000 | 52 | 0.010 |
Why?
|
| Leukopoiesis | 1 | 2000 | 2 | 0.010 |
Why?
|
| Thrombopoietin | 1 | 2000 | 11 | 0.010 |
Why?
|
| Interleukin-11 | 1 | 2000 | 8 | 0.010 |
Why?
|
| Interphase | 1 | 2000 | 68 | 0.010 |
Why?
|
| Histocompatibility Testing | 1 | 2000 | 32 | 0.010 |
Why?
|
| Epithelial Cell Adhesion Molecule | 1 | 1999 | 3 | 0.010 |
Why?
|
| Syndrome | 1 | 2000 | 179 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2001 | 578 | 0.010 |
Why?
|
| Point Mutation | 1 | 2000 | 166 | 0.010 |
Why?
|
| Hippocampus | 1 | 2001 | 267 | 0.010 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 1999 | 28 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2001 | 216 | 0.010 |
Why?
|
| Integrin alpha4beta1 | 1 | 1999 | 2 | 0.010 |
Why?
|
| Scavenger Receptors, Class A | 1 | 1999 | 6 | 0.010 |
Why?
|
| Zymosan | 1 | 1999 | 25 | 0.010 |
Why?
|
| Listeria | 1 | 1999 | 11 | 0.010 |
Why?
|
| Chemokine CXCL12 | 1 | 1999 | 17 | 0.010 |
Why?
|
| Hindlimb | 1 | 1999 | 44 | 0.010 |
Why?
|
| Motor Activity | 1 | 2001 | 344 | 0.010 |
Why?
|
| Desmosomes | 1 | 1998 | 7 | 0.010 |
Why?
|
| Erythema Nodosum | 1 | 1998 | 3 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 1998 | 47 | 0.010 |
Why?
|
| Skin Diseases, Vesiculobullous | 1 | 1998 | 5 | 0.010 |
Why?
|
| Pemphigoid, Bullous | 1 | 1998 | 3 | 0.010 |
Why?
|
| Urticaria | 1 | 1998 | 7 | 0.010 |
Why?
|
| Drug Combinations | 1 | 1999 | 165 | 0.010 |
Why?
|
| Integrins | 1 | 1999 | 109 | 0.010 |
Why?
|
| Dermatitis, Contact | 1 | 1998 | 12 | 0.010 |
Why?
|
| Rats, Inbred Strains | 1 | 1998 | 150 | 0.010 |
Why?
|
| Skin Ulcer | 1 | 1998 | 15 | 0.010 |
Why?
|
| Turtles | 1 | 1998 | 4 | 0.010 |
Why?
|
| Abatacept | 1 | 1998 | 63 | 0.010 |
Why?
|
| Thioglycolates | 1 | 1998 | 7 | 0.010 |
Why?
|
| Rats, Nude | 1 | 1998 | 25 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 1999 | 193 | 0.010 |
Why?
|
| Lac Operon | 1 | 1998 | 26 | 0.010 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2002 | 639 | 0.010 |
Why?
|
| Nitrates | 1 | 1998 | 22 | 0.010 |
Why?
|
| Tetanus Toxoid | 1 | 1998 | 14 | 0.010 |
Why?
|
| Calcium | 1 | 2001 | 574 | 0.010 |
Why?
|
| CD52 Antigen | 1 | 1997 | 4 | 0.010 |
Why?
|
| B7-1 Antigen | 1 | 1998 | 73 | 0.010 |
Why?
|
| Ceramics | 1 | 1997 | 3 | 0.010 |
Why?
|
| Lung Compliance | 1 | 1997 | 5 | 0.010 |
Why?
|
| Airway Resistance | 1 | 1997 | 8 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 1998 | 70 | 0.010 |
Why?
|
| Hematopoietic Cell Growth Factors | 1 | 1997 | 4 | 0.010 |
Why?
|
| STAT5 Transcription Factor | 1 | 1997 | 14 | 0.010 |
Why?
|
| Janus Kinase 2 | 1 | 1997 | 15 | 0.010 |
Why?
|
| Mucous Membrane | 1 | 1997 | 22 | 0.010 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1997 | 34 | 0.010 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 1997 | 93 | 0.010 |
Why?
|
| Mesoderm | 1 | 1997 | 84 | 0.010 |
Why?
|
| STAT1 Transcription Factor | 1 | 1997 | 35 | 0.010 |
Why?
|
| N-Glycosyl Hydrolases | 1 | 1996 | 12 | 0.010 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 1 | 1996 | 11 | 0.010 |
Why?
|
| Peripheral Nervous System | 1 | 1996 | 10 | 0.010 |
Why?
|
| Phosphatidylinositols | 1 | 1997 | 52 | 0.010 |
Why?
|
| Digestive System | 1 | 1996 | 27 | 0.010 |
Why?
|
| Tyrosine | 1 | 1997 | 93 | 0.010 |
Why?
|
| Lewis X Antigen | 1 | 1996 | 6 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 1996 | 6 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 1996 | 24 | 0.010 |
Why?
|
| DNA, Satellite | 1 | 1996 | 16 | 0.010 |
Why?
|
| Beta-Globulins | 1 | 1976 | 1 | 0.010 |
Why?
|
| Dysgammaglobulinemia | 1 | 1996 | 1 | 0.010 |
Why?
|
| Alpha-Globulins | 1 | 1976 | 4 | 0.010 |
Why?
|
| Meiosis | 1 | 1996 | 64 | 0.010 |
Why?
|
| Granulosa Cells | 1 | 1996 | 16 | 0.010 |
Why?
|
| Anodontia | 1 | 1996 | 1 | 0.010 |
Why?
|
| Incisor | 1 | 1996 | 7 | 0.010 |
Why?
|
| Isoenzymes | 1 | 1996 | 140 | 0.010 |
Why?
|
| Serum Albumin | 1 | 1976 | 46 | 0.010 |
Why?
|
| Receptors, Antigen, B-Cell | 2 | 1991 | 60 | 0.010 |
Why?
|
| Phosphoproteins | 1 | 1997 | 219 | 0.010 |
Why?
|
| Transfection | 1 | 1998 | 691 | 0.010 |
Why?
|
| Organelles | 1 | 1996 | 20 | 0.010 |
Why?
|
| Pyloric Antrum | 1 | 1995 | 4 | 0.010 |
Why?
|
| Neuroimmunomodulation | 1 | 1995 | 7 | 0.010 |
Why?
|
| Duodenum | 1 | 1995 | 42 | 0.010 |
Why?
|
| Ovary | 1 | 1996 | 99 | 0.010 |
Why?
|
| S Phase | 1 | 1995 | 78 | 0.010 |
Why?
|
| Protein Processing, Post-Translational | 1 | 1997 | 262 | 0.010 |
Why?
|
| Minor Lymphocyte Stimulatory Antigens | 1 | 1995 | 1 | 0.010 |
Why?
|
| Globins | 1 | 1995 | 25 | 0.010 |
Why?
|
| Gonadal Steroid Hormones | 1 | 1995 | 31 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1995 | 104 | 0.010 |
Why?
|
| Erythroid Precursor Cells | 1 | 1995 | 23 | 0.010 |
Why?
|
| HLA-DR Antigens | 1 | 1994 | 26 | 0.010 |
Why?
|
| Central Nervous System | 1 | 1996 | 197 | 0.010 |
Why?
|
| Body Burden | 1 | 1994 | 12 | 0.010 |
Why?
|
| Orchiectomy | 1 | 1994 | 31 | 0.010 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 1994 | 87 | 0.010 |
Why?
|
| Estrogen Replacement Therapy | 1 | 1994 | 80 | 0.010 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 1995 | 144 | 0.010 |
Why?
|
| Ovariectomy | 1 | 1994 | 102 | 0.010 |
Why?
|
| Clinical Protocols | 1 | 1995 | 138 | 0.010 |
Why?
|
| Histocompatibility Antigens | 1 | 1994 | 107 | 0.010 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 1994 | 85 | 0.010 |
Why?
|
| Thyroid Hormones | 1 | 1994 | 78 | 0.010 |
Why?
|
| Immunoglobulin D | 2 | 1986 | 8 | 0.010 |
Why?
|
| Protoplasts | 1 | 1973 | 4 | 0.010 |
Why?
|
| Microscopy, Phase-Contrast | 1 | 1973 | 14 | 0.010 |
Why?
|
| Densitometry | 1 | 1973 | 12 | 0.010 |
Why?
|
| Artifacts | 1 | 1994 | 128 | 0.010 |
Why?
|
| Virus Integration | 1 | 1992 | 32 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 1992 | 58 | 0.010 |
Why?
|
| Chromatography | 1 | 1971 | 16 | 0.010 |
Why?
|
| Filtration | 1 | 1971 | 20 | 0.010 |
Why?
|
| Bacillus subtilis | 1 | 1971 | 31 | 0.010 |
Why?
|
| Viscera | 1 | 1991 | 10 | 0.010 |
Why?
|
| Plasma | 1 | 1971 | 37 | 0.010 |
Why?
|
| Blood Proteins | 1 | 1971 | 76 | 0.010 |
Why?
|
| Triiodothyronine | 1 | 1991 | 29 | 0.010 |
Why?
|
| Drug Stability | 1 | 1971 | 143 | 0.010 |
Why?
|
| Cytological Techniques | 1 | 1991 | 26 | 0.010 |
Why?
|
| Hot Temperature | 1 | 1971 | 130 | 0.010 |
Why?
|
| Reference Values | 1 | 1991 | 335 | 0.010 |
Why?
|
| Blood Platelets | 1 | 1971 | 101 | 0.010 |
Why?
|
| Antibodies, Bacterial | 1 | 1971 | 194 | 0.010 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1990 | 109 | 0.010 |
Why?
|
| Macrophage-Activating Factors | 1 | 1988 | 2 | 0.000 |
Why?
|
| Aged, 80 and over | 1 | 1998 | 5408 | 0.000 |
Why?
|
| Dextrans | 1 | 1988 | 46 | 0.000 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 1988 | 112 | 0.000 |
Why?
|
| Culture Media | 1 | 1988 | 79 | 0.000 |
Why?
|
| DNA, Recombinant | 1 | 1986 | 46 | 0.000 |
Why?
|
| Cystic Fibrosis | 1 | 1987 | 118 | 0.000 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 1985 | 51 | 0.000 |
Why?
|
| Molecular Weight | 1 | 1985 | 188 | 0.000 |
Why?
|
| Cell Transformation, Viral | 1 | 1984 | 15 | 0.000 |
Why?
|
| Simian virus 40 | 1 | 1984 | 17 | 0.000 |
Why?
|
| Antigen-Antibody Complex | 1 | 1984 | 52 | 0.000 |
Why?
|
| Sarcoma, Experimental | 1 | 1982 | 6 | 0.000 |
Why?
|
| Mitogens | 1 | 1982 | 10 | 0.000 |
Why?
|
| Mice, Inbred AKR | 1 | 1981 | 12 | 0.000 |
Why?
|
| Pigmentation | 1 | 1981 | 25 | 0.000 |
Why?
|
| Antibody-Producing Cells | 1 | 1978 | 12 | 0.000 |
Why?
|
| Concanavalin A | 1 | 1978 | 40 | 0.000 |
Why?
|
| Antibody Formation | 1 | 1978 | 113 | 0.000 |
Why?
|